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Chapter1 
 
GENERAL ISSUES IN PROTEOMICS 
In this first chapter we will deal with the basics for biologic and clinical applications of 
proteomics. The technique was developed in the early ‘90ies as a development of the high 
resolution bidimensional electrophoretic techniques of protein identification originally set-
up by O’Farrell to study expression of proteins in E.coli cells and its coupling with mass 
spectrometric identification of proteins. At the early time the procedure was applied to 
basic studies of proteins chemistry, including sequencing and folding as described by 
Wilkins and associates (1996), who were among the first authors to apply the term 
proteomics for a general application  of the concept to biologic investigations.  The 
potentials of the technique for elucidation of complex issues was definitely apparent when 
Nair et al (2004) reviewed in Am. J. Physiol. their application in the field of physiology 
and therefore in pathology. In their review these authors state that this advancement is a 
consequence of the whole human genome sequencing so that it is possible to identify any 
protein from their sequence to couple its variation in tissue levels to physiologic pathologic 
events. Actually these authors state that “ the term “proteome” refers to the collection of 
proteins within a cell , tissue, or entire organism and was first coined to describe large-
scale protein identification and amino acid analysis. The study of the proteome, or 
proteomics, has moved beyond cataloguing of proteins in an organism and now includes 
the comprehensive and detailed analysis of proteins…..” in an issue that is now 
appreciated as more complex than genomics because it includes also proteins that are post-
translationally modified for regulatory purposes.  
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Thus, if the main concept is the utilization of proteomics to identify tissular proteins, this i 
s also a procedure  to obtain information about the functions of cells and tissues they are 
contained in under physiological and pathological conditions as summarised in the 
following table  
 
  Proteomics: objectives for potential application in human research 
1) Identify proteins or protein involved in diseases 
2) Identify modifications of proteins causing complications, e.g., nonenzymatic glycosylation 
of proteins in diabetes and structural modification (folding changes) 
3) Identify molecular pathways involved in functional changes, e.g., signal transduction 
4) Target drugs to specific proteins or pathway involved in disease 
 
At the same time, as it is evident in points 2 and 3 of the table, the potential of the 
approach is so efficient to include fine modification of the protein structure that are 
relevant to protein function (i.e. in the field of “functional proteomics”).  All this stems 
from the concept that proteins are indeed  functional molecules, and that their study is of 
major interest to physiologists and physician scientists. The new technologies now 
available offer new perspectives because one protein may cause cascade effects and change 
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the synthesis rate, modifications, and folding of several other proteins, so that large scale 
of  proteomics may yield crucial information on regulation of body functions and the 
mechanism of diseases. However, the proteomic technologies are still not sufficiently 
precise and sensitive enough to detect subtitle changes in concentrations of proteins that 
occur during acute physiological interventions. At the same time one must be aware that 
proteins that are newly synthesized may get degraded immediately (fast turnover of 
proteins), and changes in detectable levels of concentration may not occur. In addition 
many protein functions are also altered by modifications (i.e., phosphorylation or 
glycation) without a change in concentration. Metabolic labeling in vivo with stable 
isotopes and identification of proteins whose synthesis rates change during an intervention 
may enable us to detect changes that could not be detected by profiling and quantification 
alone. Improvements in the techniques to accurately purify proteins from a mixture, 
quantification of samples with greater precision, and detection of the enrichment of stable 
isotope tracers in small sample sizes will help to advance our existing capabilities. Further 
advances in simultaneous detection of modification of multiple proteins in biological fluids 
and tissue proteins are also essential to fully understand the regulation of functions and the 
alterations that occur in diseases. 
Since the main information that is obtained through proteomic investigations is related to 
changes in tissue concentration of single proteins, from the biological point of view an 
immediate interest of the proteomic research is related to the field of modulation of protein 
expression through variation in their biosynthetic rate. This is exemplified by the issues of  
Systems biology, that is the analysis of the relationships among the elements in a system in 
the response to genetic or environmental perturbations, with the goal of understanding the 
system or the emergent properties of the system. A system may be a few protein molecules 
carrying out a particular task (such as metabolism of galactose or any other specific 
metabolite); a complex set of proteins and other molecules physically associated or 
working together as a molecular machinery (such as the ribosome); a network of proteins 
operating together to carry out an important cellular function such as giving the cell shape 
(protein network), or a cell or group of cells carrying out particular phenotypic functions. 
Thus, a biological system may encompass molecules, cells, organs, individuals, or even 
ecosystems. System biology will continually improve our capacity to understand and to 
model biological systems on a more global and in-depth scale than ever before. The 
systems biology in medicine will be continual with the development of new technologies, 
which will enhance  efficiency, scale and precision with which cellular measurements are 
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made. This later influence will facilitate all aspects of health care, including the detection 
and monitoring of diseases, drug discovery, treatment evaluation, and ultimately, 
predictive and preventative medicine.  
As already pointed out a main usefulness of proteomic investigations is related to the 
analysis of qualitative/ quantitative changes in tissue protein content. These changes are 
usually ascribed to variations in the cell protein synthetic potential, but this is certainly an 
oversimplification, since several other effects might contribute to a final pattern 
documented by the experimental techniques, including chiefly protein breakdown, as in red 
blood cells. What is now clearly emerging is that - thanks to their high sensitivity and 
versatility - proteomic techniques can provide answers to complex sets of queries when 
rationally employed within an experimental design. In the perspective of biological and 
medical applications, results of proteomic experiments can be interpreted to solve 
experimental and clinical issues. This subdivision displays certainly borderline effects and 
is therefore questionable so that we prefer to merge it somewhat in this short discussion of 
the usefulness of proteomic investigations, taking into account a few selected examples. 
This thesis is devoted to these issues and will proceed hrough a short description of the 
experimental approaches that are employed in proteomic research (Chapter 2), and further 
with a few examples of topics in the field of experimental biologic and of clinical research 
that might be faced through proteomic techniques (chapter 3) before entering the 
experimental investigations I have carried out both in the field of basic and clinical 
research. The aim is certainly not that to be exhaustive in the treatise but to summarize the 
few issues I took in account which include protein posttranslational modification (focusing 
on the action of human transglutaminase on troponin, tubulin and dyphtheria toxin) and 
issues in cancer research spanning from identification of cancer biomarkers - in relation to 
breast cancer - to the event of Epidermal Mesenchimal Transition  to which now much 
interest is dedicated because this process is believed to be crucial in determining  
aggressive behaviour of cancers in mammals.   
Some of these results have already been published. Other reports are now in progress to 
describe completely my efforts in the scientific literature  
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Chapter 2 
 
METHODOLOGIES FOR PROTEOME ANALYSIS 
 
The steps involved in basic proteomic investigations include: 1) a pre-analytical stage that 
involves solubilization of the samples in appropriate solvents and eventually steps of 
partial purification and enrichment in the particular sub-fractions that are submitted to 
analysis; 2) an analytical stage itself comprising two phases; in the first the  proteins are 
either resolved from each other by 2D electrophoresis or directly submitted to proteolysis 
before separation of the released peptide by liquid chromatography; in the second 
individual spots in the stained 2D gels are digested with proteases and the released peptides 
or selected peptides from LC chromatograms are fed to matrixes from which the peptides 
are detached in ionized form and analyzed by MS/MS and TOF to deduce their m/z ratios; 
and 3) final post-analytical stage in which the data derived by the successive fragmentation 
procedures are compared with those present in PDB to deduce the identity of the protein 
itself. 
These considerations apply to any protein sample including those that have been selected 
for any peculiarity such as phosphorylated proteins, glycosylated proteins or proteins that 
are secreted from cultured cells. In other words these kinds of research are extremely 
flexible and can be applied to any significant experimental system. 
The methodologies that are employed in proteomic investigations will now be basically 
described according to this general scheme and the main variations that are employed 
when dealing with peculiar samples or with different aims are also briefly outlined. 
 
THE PRE-ANALYTICAL STEPS   
 
In general terms the sample might be represented by a solution of protein (e.g. plasma), a 
tissue or even a fixed tissue sample of the type that is employed in pathologic research and 
diagnosis. 
In the case of solutions of proteins they may be mixed with solubilization buffer at a rather 
basic pH (around 9.0) containing chaotropic reagents (urea and thiourea) and non ionic 
detergents (usually Chaps or ASB 14) and mix of proteases inhibitors to avoid digestion of  
the  sample proteins that would be facilitated by the presence of the denaturants that unfold 
proteins and make them more susceptible to proteolysis. The settlement is followed in the 
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case the sample has suitable concentration of proteins to allow optimal loading in the 
subsequent separation step and that the interst of the research is focusing on the major 
proteins in the sample. 
In other conditions it may be important to concentrate the proteins or eventually to enrich 
the fraction of minor proteins if these represent the aim of the determination. 
Procedures for concentration may be represented by lyophilization or high performance 
precipitation. This last step is usually carried out using solution of strong acids like TCA in 
acetone. This mix is capable of quantitative protein precipitation even from very dilute 
protein solutions such as 50 micrograms/ml. Procedures for enrichment of minor proteins 
in the sample are usually denoted as depletion of major proteins.  Examples for these 
requirements are represented for instance by the analysis of the protein in red blood cell 
lysates (where the enormous amounts of hemoglobin – about 95% of total proteins - would 
prevent the possibility to analyze the cytosolic enzymes) or the analysis of plasma where 
albumin and immunoglobulins would represent  about 80% of the total proteins. In these 
cases removal of the major proteins might be achieved by immunoprecipitation or by 
chromatographic depletion by cation exchange chromatography of cyano-Methemoglobin. 
Alternatively the sample might be treated with Proteominer, which is a library of peptides 
which are immobilized on a matrix in equivalent moderate amounts. This issue is 
represented schematically below 
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Schematic representation of Proteominer Treatment using Proteominer beads and SDS-
PAGE analysis of Proteominer bead-treated plasma. 
 
The Proteominer technology is a novel sample preparation tool used for the compression of 
the dynamic range of the protein concentration in complex biological samples. High-
abundance proteins present in complex biological samples like sera or plasma, make the 
detection of medium- and low abundance proteins extremely challenging. This technology 
provides a method of overcoming this challenge, allowing for the exploration of the entire 
proteome. 
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This is accomplished through the use of a large, highly diverse bead-based library of 
combinatorial peptide ligands. When complex biological samples are applied to the beads, 
the high-abundance proteins saturate their high affinity ligands and excess protein is 
washed away. In contrast, the medium- and low abundance proteins are concentrated on 
their specific affinity ligands. This reduces the dynamic range of protein concentrations 
while maintaining representatives of all proteins within the original sample. 
In the case the sample is represented by a tissue or  isolated cells (these are models that 
have been analysed in the present thesis) the proteins must be extracted from the cells by 
homogenization with the same lysis buffer as above employed mechanical protein 
dispersion with a Potter-Elverhjem apparatus in the case of solid tissues or vortexing and 
long-lasting stirring in a rotatory wheel in the case of isolated cells (e.g. blood cells or the 
cholangio-carcinoma cells we have submitted to proteomic analysis, see below). After 
these steps of protein extraction, cellular debris, collagne or DNA are removed by 
centrifugation or syringe needle squeezing, depending on the individual requirements. 
If the proteins are contained in a fixed sample as the Formalin Fixed Paraffin Embedded 
(FFPE) tissues that are employed in pathologic research tissue slices are extracted with 
solutions containing SDS and reducing agents at 100  to 80 °C and the detergent is 
removed by Acid Acetone protein precipitation. Released proteins are thereafter separated 
by IEF-SDSPAGE. Alternatively for shotgun approaches slices of FFPE tissues are treated 
with SDS-DTT-ammonium carbonate buffer at lower temperature after hexane extraction 
to remove paraffin (this treatment effectively breaks down protein crosslinks by formalin) 
and treated with trypsin in the presence of high concentrations of CaCl2. In this way 
soluble peptides are released that can be directly analysed by LC-MS. 
 
THE ANALYTICAL STEPS   
 
These obviously vary according to the 2D electrophoretic or to the LC approach. In the 
first instance the protein mixture is resolved in a first dimension by IsoElectricFocusing 
(IEF) and in a second dimension by SDS-PAGE in a slab gel, which is stained by a 
procedure compatible with digestion by proteinases to identify and select isolated proteins  
to be analyzed, directly within gel fragments (in situ digestion). The released peptides are 
then submitted to MS analysis. In the LC approach instead the digestion is performed 
directly on the sample before resolving the peptides by hplc. The main difference is 
therefore that the first approach (the one we have employed in the present research),  
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provides directly some basic information on the differential tissue protein expression, 
which is not available for the LC-MS approach unless procedure of difference sample 
labeling are employed. 
High-resolution two-dimensional electrophoresis (2-D PAGE) for the separation of 
complex protein mixtures was introduced by (O’Farrell et.al 1975) by combining 
isoelectric focusing (IEF) in the first dimension in presence of urea, detergents and DTT, 
with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in the 
second dimension.  
 
Representation of 2D-electrophoresis of breast cancer tissue 
 
Proteins are separated according to isoelectric point (pI) and molecular mass (Mr), and 
quantified according to relative abundance. Depending on the gel size and pH gradient 
used, 2-D PAGE can resolve more than 5,000 proteins simultaneously (~2,000 proteins 
routinely), and can detect <1 ng of protein per spot. 
Furthermore, it delivers a map of intact proteins, which reflects changes in protein 
expression level, isoforms or post-translational modifications. An additional strength of 2-
D PAGE is its capability to study proteins that have undergone some form of post-
translational modification (such as phosphorylation, glycosylation or limited proteolysis) 
and which can – in many instances - be readily located in 2-D gels as they appear as 
distinct ‘spot trains’ in the horizontal and /or vertical axis of the 2-D gel.  In addition, 2-D 
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PAGE not only provides information on protein modifications and/or changes in their 
expression levels, but also permits the isolation of proteins for further structural analyses 
by MALDI-ToFMS or ESI-MS .  
Despite these benefits, a major problem of 2-D PAGE has been the exchange of 2-D gel 
data between laboratories due to spatial irreproducibility between 2-D gels generated by 
the conventional method of 2-D PAGE using carrier ampholyte (CA) IEF. Equilibrium 
CAIEF cannot be achieved because of pH gradient instability with prolonged focusing 
time, as the pH gradient moves towards the cathode (‘cathodic drift’) and flattens in the 
centre (‘plateau phenomenon’). Consequently, time-dependent protein patterns are 
obtained. In addition, reproducibility of pH gradient profiles is limited by the batch-to-
batch variability of CA preparations. 
The problems of pH gradient instability and irreproducibility were overcome by the 
introduction of immobilized pH gradients (IPG) for IEF (Bjellqvist et al. 1982), (Görg et 
al. 1988). IPGs are based on the principle that the pH gradient is generated by a limited 
number (<10) of well-defined chemicals (the ‘Immobilines’) which are co-polymerized 
with the acrylamide matrix. Thus cathodic drift is eliminated, reproducibility enhanced and 
pattern matching and inter-laboratory comparison simplified. IPGs allow the generation of 
pH gradients of any desired range (broad, narrow or ultra-narrow) between pH 2.5 and 12. 
Since sample loading capacity of IPG-IEF is also higher than with CA-IEF, especially in 
combination with narrow (1 pH unit) or ultra-narrow (0.1 pH unit) IPGs, 2-D PAGE with 
IPGs is the method of choice for micropreparative separation and spot identification. 
The protein spots that are considered to vary in the sample according to the experimental 
parameters taken into account are identified in stained gels (either colloidal Coomassie 
stain or Silver nitrate staining are acceptable) are then digested with trypsin or other 
suitable proteinases (e.g. staphylococcal V8 proteinase) with high sequence and amino acid 
specificity.  
As already mentioned in the LC-MS approach the  peptides that will be later employed for 
protein identification are generated by digestion of the soluble proteins in the sample 
extract at an early step, before any attempt to fractionation procedures.  LC-MS is  used in 
proteomics where again components of a complex mixture must be detected and identified 
in some manner. The LC-MS approach to proteomics generally involves protease digestion 
and denaturation (usually trypsin as a protease, urea to denature tertiary structure and 
iodoacetamide to cap cysteine residues) followed by LC-MS with peptide mass 
fingerprinting or LC-MS/MS (tandem MS) to derive sequence of individual peptides. LC- 
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MS/MS is most commonly used for proteomic analysis of complex samples where peptide 
masses may overlap even with a high-resolution mass spectrometer. Samples of complex 
biological fluids like human serum may be run in a modern LC-MS/MS system and result 
in over 1000 proteins being identified.  
Once the peptides have been obtained they are submitted to HPLC chromatographic which 
is technique used to separate a mixture of compounds in analytical chemistry and 
biochemistry with the purpose of identifying, quantifying and purifying the individual 
components of the mixture. HPLC typically utilizes different types of stationary phases 
(i.e. sorbents) contained in columns, a pump that moves the mobile phase and sample 
components through the column, and a detector capable of providing characteristic 
retention times for the sample components and area counts reflecting the amount of each 
analyte passing through the detector. The detector may also provide additional information 
related to the analyte, (i.e. UV/Vis spectroscopic data, if so equipped). Analyte retention 
time varies depending on the strength of its interactions with the stationary phase, the 
composition and flow rate of mobile phase used, and on the column dimensions. HPLC is a 
form of liquid chromatography that utilizes small size columns (typically 250 mm or 
shorter and 4.6 mm i.d. or smaller; packed with smaller particles), and higher mobile phase 
pressures compared to ordinary liquid chromatography. With HPLC, a pump (rather than 
gravity) provides the higher pressure required to move the mobile phase and sample 
components through the densely packed column. The increased density arises from the use 
of smaller sorbent particles. Such particles are capable of providing better separation on 
columns of shorter length when compared to ordinary column chromatography. 
In this instance the peptides that are resolved during the chromatographic procedure are 
directly to  the mass spectrometer. 
The identification of the parent protein is then achieved by Mass Spectrometry of which 
several types have been described based basically on the procedure employed to generate 
ionized peptides on which m/z ratio are determined. They are mainly the MALDI and the 
ESI procedures.  
In the case of Matrix-assisted laser desorption/ionization (MALDI) the technique  used in 
mass spectrometry is a soft ionization procedure allowing the analysis of biomolecules 
(biopolymers such as DNA, proteins, peptides and sugars) and large organic molecules 
(such as polymers and other macromolecules), which tend to be fragile and fragment when 
ionized by more conventional ionization methods. It is similar in character to electrospray 
ionization both in relative softness and the ions produced (although it causes many fewer 
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multiply charged ions. MALDI is a two step process. In the first, the sample is absorbed on 
a matrix, from which desorption (the second step) is triggered by a UV laser. Matrix  
material heavily absorbs UV laser light, leading to the ablation (removal of material from 
the surface of an object by vaporization, chipping, or other erosive processes). of upper 
layer (~micron) of the matrix material. A hot plume produced during the ablation contains 
many species: neutral and ionized matrix molecules, protonated and deprotonated matrix 
molecules. The second step is ionization (more accurately protonation or deprotonation). 
Protonation (deprotonation) of analyte molecules takes place in the hot plume. Some of the 
ablated species participate in protonation (deprotonation) of analyte molecules.                                                                
The Matrix is a crucial component whose function is adsorption of energy from laser 
pulse, and then transfer to sample thereby causing desorption of the analyte molecules in 
an expanding plume, to ionize the desorbed analyte molecules and to prevent aggregation 
of the analyte molecules. The matrix molecules for MALDI are chosen on the basis of 
fulfillment of requirement that matrix molecules must be able to absorb ultra violet 
wavelength of usually 237 nm, low volatility and ability to transfer protons to the sample 
molecules. For proteins samples typical MALDI matrix consist of cinnamic acid and 
hydroxylated benzoic acid derivatives. The whole process is summarized below. The 
signal that is generated and analysed in this kind of mass spectrometry is known as Time-
of-flight mass spectrometry (TOFMS) which is a method of mass spectrometry in which 
an ion's mass-to-charge ratio is determined via a time measurement. Ions are accelerated by 
an electric field of known strength. This acceleration results in an ion having the same 
kinetic energy as any other ion that has the same charge. The velocity of the ion depends 
on the mass-to-charge ratio. The time that it subsequently takes for the particle to reach a 
detector at a known distance is measured. This time will depend on the mass-to-charge 
ratio of the particle (heavier particles reach lower speeds). 
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Representation of MALDI-TOF 
 
An alternative procedure for ionization of peptides and feeding to the mass spectrometer is 
Electrospray ionization (ESI) which is a technique used to produce ions in mass 
spectrometry. It is especially useful in producing ions from macromolecules because it 
overcomes the propensity of these molecules to fragment when ionized. The liquid 
containing the analyte(s) of interest is dispersed by electrospray into a fine aerosol. 
Because the ion formation involves extensive solvent evaporation, the typical solvents for 
electrospray ionization are prepared by mixing water with volatile organic compounds (e.g. 
methanol, acetonitrile). To decrease the initial droplet size, compounds that increase the 
conductivity (e.g. acetic acid) are customarily added to the solution. Large-flow 
electrosprays can benefit from additional nebulization by an inert gas such as nitrogen. The 
aerosol is sampled into the first vacuum stage of a mass spectrometer through a capillary, 
which can be heated to aid further solvent evaporation from the charged droplets. The 
solvent evaporates from a charged droplet until it becomes unstable upon reaching its 
Rayleigh limit. At this point, the droplet deforms and emits charged jets in a process 
known as Coulomb fission. During the fission, the droplet loses a small percentage of its 
mass (1.0-2.3%) along with a relatively large percentage of its charge (10-18%) (Kebarle 
P.et.al 2009). 
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Schematic representation of ESI-MS 
 
Ion Trap 
An ion trap is a combination of electric or magnetic fields that captures ions in a region of 
a vacuum system or tube. Ion traps have a number of scientific uses such as mass 
spectrometry and trapping ions while the ion's quantum state is manipulated. The two most 
common types of ion traps are the Penning trap and the Paul trap (quadrupole ion trap). 
When using ion traps for scientific studies of quantum state manipulation, the Paul trap is 
most often used. An ion trap mass spectrometer may incorporate a Penning trap (Fourier 
transform ion cyclotron resonance),(Blaum,Klaus. 2006) Paul trap or the Kingdon trap. 
Other types of mass spectrometers may also use a linear quadrupole ion trap as a selective 
mass filter. These procedures are complicate and will not further dealt with in this study 
which is amied to demonstrate applicability of proteomic procedures to solve biologically 
or clinically relevant issues.  
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The complexity of the signals that are obtained is particularly evident during attempts of 
Gel-independent quantitative profiling of the proteome. The combination of LC-MA/MS 
and sequence database searching has been widely adopted for the analysis of complex 
peptide mixtures generated from the proteolysis of samples containing several proteins. 
This approach is often referred to as ‘shotgun’ proteomics and has the ability  to catalog 
hundred, or even thousands, of components contained in sample isolated from very 
different sources. Specific examples include the identification of proteins in the 
periplasmic space of bacteria, yeast ribosomal complexes, murine nuclear interchromatin 
granule cluster, human urinary proteins, proteasomal proteins etc.  
Such studies have also highlighted the limitations of shotgun proteomics, including, the 
difficulty of detecting by collision-induced dissociation (CID) mass spectrometry all of the 
peptides in a sample, the qualitative nature of data-dependent experiments, and the 
challenge of processing the tens of thousands of CID spectra generated in a typical 
experiment. On average, a protein digested with trypsin will generate 30-50 different 
peptides. A tryptic digest of the of a typical human cell will therefore generate a peptide 
mixture containing at least hundreds of thousands of peptide. Even the most advanced LC-
MS/MS system cannot resolve and analyze such complexity in a reasonable amount of 
time.  
To use LC-MS/MS for the analysis of most proteomes, therefore, a form of complexity 
reduction (fractionation) is required. Two approaches have been developed to tackle this 
problem. The first approach is the selective enrichment of a subset of peptides from a 
complex mixture. This has been mostly achieved by specifically targeting peptides that 
contain a distinguishing feature, such as chemically reactive sulfhydryl groups (cysteine 
residues) or residues that has been modified post-translationally with phosphate or 
carbohydrate. Ideally, such strategies would select precisely one idiotypic peptide per 
protein. Although this has not been realized, substantial reductions in same complexity 
have been achieved. The trade-off is the loss of proteins that do not contain the selected 
feature.   
The second approach relies on extended upstream fractionation of the complex peptide 
mixtures, with the aim of increasing the potential of the mass spectrometer to detect and to 
sequence all of the components of the sample. This has been implemented by using two or 
three orthogonal peptide separation methods in sequence, the most powerful of which have 
involved cation exchange and capillary reverse-phase chromatography. Although both 
approaches either by themselves or in combination have produced evidence that proteome 
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cataloguing using such proteomic strategies is feasible, a complete map of  the proteome  
of any species has yet to be produced by any method.  
To turn shotgun proteomics into a quantitative protein profiling method, therefore, stable 
isotope dilution has been combined with the complexity reduction technique.  
The first such approaches was based on a class of reagent termed ‘isotope-coded affinity 
tags or ICAT’, LC-MS/MS and sequence database searching. The reagents consist of an 
alkylating group (iodoacetic acid) that covalently attaches the reagent to reduced cysteine 
residues, a polyether mass-encoded linker containing either eight hydrogen (d0) or eight 
deuterium (d8) that represents the isotope dilution and a biotin affinity tag through which 
tagged peptides are selectively isolated.  
 
Quantitative proteomics using ICAT reagents. 
 
After optional protein enrichment and enzymatic digestion of the combined samples, the 
biotinylated ICAT-labeled peptides are enriched by means of avidin affinity 
chromatography and analyzed by LC-MS/MS. Each cysteinyl peptide appears as a pair of 
signals differing by the mass differential encoded in the mass tag. The ratio of these signal 
intensities precisely indicates the ratio of abundance of the protein from which the peptide 
originates, and the MS/MS spectrum of either isotopic form of the peptide allows the 
protein to be identified. Thus, in a single, automated operation this method identifies the 
proteins present in two related samples and determines the ratio of relative abundance. 
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Although isotope-tagging methods based on chemical labeling after isolation are 
compatible with essentially any protein sample, including organelles, body fluids or 
subcellular and biochemical fractions, the application of metabolic labeling is limited to 
those situations in which cells can be in isotopically defined media. 
 
THE POST-ANALYTICAL STEPS   
 
These are represented by the computational approaches that are employed for the 
identification of any protein structure from the fragments (peptides) that have been 
evidenced during the fragmentation and mass spectrometry steps. Although additional 
procedures have been developed, that we have relied on is the Mascott software which is a 
powerful search engine which uses mass spectrometry data to identify proteins from 
primary sequence databases. By using an appropriate scoring algorithm, the closest match 
or matches can be identified. If the "unknown" protein is present in the sequence database, 
then the aim is to pull out that precise entry. If the sequence database does not contain the 
unknown protein, then the aim is to pull out those entries which exhibit the closest 
homology, often equivalent proteins from related species. The algorithm MOWSE is more 
selective and sensitive than other algorithms calculating only number of matching peptides. 
Calculating estimates it takes into consideration both relative excess of peptides of the 
same molecular mass in the database and size of protein. Program MASCOT is based on 
the MOWSE algorithm; this program also evaluates a possibility of random matching of 
experimental and theoretical peptide masses. Using sequential queries MASCOT can 
optimize search parameters. Using this program it is possible to identify proteins in 
relatively simple mixtures. 
Mascot is a search engine based on mass spectrometry data to identify proteins using 
primary sequence databases. There are primarily three types of searches namely peptide 
mass fingerprint method (based on a list of peptide mass values generated from an 
enzymatic digest of a protein) sequence query method (based on one or more peptide mass 
values associated with information such as partial or ambiguous sequence strings, amino 
acid composition information, MS/MS fragment ion masses) and MS/MS ion search 
method (based on identification based on raw MS/MS data from one or more peptides). 
Mascot looks for the highest scoring set of peptide matches which are within a contiguous 
stretch of sequence less than or equal to the specified protein molecular weight. The 
optimum data set for a peptide mass fingerprint is, of course, all of the correct peptides and  
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none of the wrong ones. The sequence query mode of Mascot supports both standard and 
error tolerant sequence tags. It also allows arbitrary combinations of fragment ion mass 
values, amino acid sequence data and amino acid composition data to be searched.  
Given an absolute probability that a match is random, and knowing the size of the 
sequence database being searched, it becomes possible to provide an objective measure of 
the significance of a result. A commonly accepted threshold is that an event is significant if 
it would be expected to occur at random with a frequency of less than 5%. This is the value 
which is reported on the master results page. The master results page for typical peptide 
mass fingerprint search reports that "Scores greater than 67 are significant (p<0.05)". The 
protein with the high score of 108 is a 26 kDa heat shock protein from yeast. This is a nice 
result because the highest score is highly significant, leaving little room for doubt. 
 
SOME SPECIALIZED APPLICATIONS OF  PROTEOMICS 
 
One of these is represented by the study of protein phosphorylation which has prominent 
importance in the biological events of signal transduction. For these purposes identification 
of phosphopeptides and of site(s) of phosphorylation has been achieved using either 
MALDITOF or electrospray mass spectrometry. For the analysis of phosphopeptides by 
MALDI-TOF, the peptide must  ionize at high level after co-crystallization with a UV 
absorbing matrix as 4-hydroxycyanno-cinnamic acid or 2,5-dihydroxybenzoic acid. 
Phosphopeptide ions undergo a characteristic loss of phosphoric acid after ionization by a 
process referred to as post source decay (PSD) and when analyzed by reflectron  MALDI  
TOF MS, the poorly resolved metastable fragments can be observed (R.S. Annan et.al 
1996). By using the new generation MALDI-TOFTOF mass spectrometers the 
phosphopeptide ions can be fragmented by either PSD or collision induced dissociation 
(CID) to generate MS/MS spectra and the position of phosphorylation can be determined 
from the fragmentation series.An alternative to this is to use a MALDI-QqTOF mass 
spectrometer with 2,5-dihydroxybenzoic acid as the matrix, which has been reported to 
yield higher quality MS/MS spectra than that obtained by a MALDI-TOF-TOF mass 
spectrometer and hence makes the assignment of the site of phosphorylation easier.  
The main limitation of using MALDI-TOF mass spectrometry for the detection and 
sequencing of phosphopeptides is they are often difficult to detect in unfractionated protein 
digests. 
Detection of phosphopeptides by specific mass spectral scanning methods based on either 
the neutral loss of phosphoric acid from phosphoserine or phosphothreonine (neutral loss 
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scan) during collision induced dissociation (CID) in positive mode, or the generation of a 
phosphate specific reporter ion after collision induced dissociation in negative mode 
(precursor ion scan). 
 
 
Scan modes used for phosphorylation site mapping. 
 
Additional interesting applications are represented by the interaction proteomics and the 
subcellular proteomics. The former is investigated taking advantage of 
immunoprecipitation studies are another useful way to exploit the resolving power of 
proteomics, dealing with the protein-protein interactions in cells and in lysates that might 
play important roles in metabolic regulation. In this instance, very large quantities of 
protein can be subjected to incubation with antibodies against chosen signaling molecules. 
This allows high-affinity capture of these proteins, which can subsequently be eluted and 
electrophoresed on a 2D gel to provide a high-resolution proteome of a specific subset of 
proteins. Detection by blot analysis allows the identification of extremely small amounts of 
defined signaling molecules. Again, the different isoforms of even very low abundance 
proteins can be seen, and, very importantly, the technique allows the investigator to 
identify multiprotein complexes or other proteins that co-precipitate with the target protein. 
These coassociating proteins frequently represent signaling partners of the target proteins, 
and their identifications by mass spectrometry can lead to invaluable information on the 
signaling processes involved. 
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The depth of signal transduction analysis offered by proteomics, and the utility for target 
validation studies can be extended even further by applying cell fractionation studies 
(Corthals, G,L et.al 1997).  By purifying subcellular fractions, such as membrane, nuclear, 
organelle and cytosolic, it is possible to assign a localization to proteins of interest and to 
follow their trafficking in a cell. Enrichment of these fractions will also allow much higher 
representation of low abundance proteins on the proteome. These signal transduction 
analyses can be of additional value in experiments where inhibitors derived from a 
screening program against the target are being evaluated for their potency and selectivity. 
The inhibitors can encompass small molecules, antisense nucleic acid constructs, 
dominant-negative proteins, or neutralizing antibodies microinjected into cells. In each 
case, proteome analysis can provide unique data in support of validation studies for a 
chosen candidate drug target. 
Another approach which has been of special interest in our laboratory is that of 
Secretomics, that might be useful for the identification of several clinically relevant 
biomarkers as for instance in the case of cancer proteomics. “Secretome” is referred to as 
the rich, complex set of molecules secreted from living cells, the term also includes 
molecules shed from the surface of living cells. Proteins of secretome play a key role in  
cell signaling, communication and migration. The need for developing more effective 
cancer biomarkers and therapeutic modalities has led to the study of cancer cell secretome 
as a means to identify and characterize diagnostic and prognostic markers and potential 
drug and therapeutic targets. 
Secreted proteins are responsible for the cross talking among cells and understanding this 
language could largely increase our knowledge on the molecular mechanisms of neoplasia. 
In addition, extracellular matrix components and other molecules secreted by tumor cells 
are a rich source of potential markers and drug targets for cancer treatment. Secreted 
proteins are also most likely excellent candidate serological tumor markers as they are 
released by the cells thus having highest possibility to enter the circulation.  
Analysis of secreted proteins is quite challenging; this may be attributed to technical 
difficulties such as a) presence of the proteins at frequently low concentrations due to their 
high dilution (in body fluids or cell culture media), b) their masking and contamination by 
cytoplasmic or other normally non secreted proteins released following cell lysis and 
death, and c) masking by serum proteins (i.e. fetal bovine serum) normally present in the 
culture media (Chevallet M,et.al 2007). These issues bunderscore the importance of 
procedures that have to be followed for cell culture and conditioned medium (CM) 
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collection so as to avoid contamination from dead cells and cytosolic proteins as well as 
for effective protein concentration, regardless the protein separation technology in use. 
 
PROTEOMICS SEPARATION TECHNIQUES FOR SECRETOME ANALYSIS 
 
A variety of proteomics methodologies have been utilized for secretome analysis including 
1D and 2D electrophoresis and liquid chromatography, all of them coupled with different 
types of MS analysis. Each of these methods has its own advantages and disadvantages 
with regards to reproducibility, quantification, identification of differentially expressed 
proteins, sensitivity and robustness. 
 
 
Schematic diagram of the experimental secretomic strategy. 
 
Recently, was performed a systematic comparison of 3 separation strategies prior to nano 
LC-MS/MS analysis: 1D gel electrophoresis (1DGE), peptide SCX (strong cation 
exchange) chromatography and tC2 protein reversed phase chromatography. 1DGE 
outperformed the SCX and tC2 methods with respect to the number of identified proteins, 
reproducibility in protein identification, and throughput. A variation of 1DGE for the study 
of secreted proteins were run on precast or home made SDS-PAGE gels and the 
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electrophoresis was stopped after the sample had barely passed from stacking into the 
resolving gel. All sample proteins were concentrated in a tight band at the top of the 
resolving gel, stained with Coomassie blue, excised, digested with trypsin and processed 
for MS analysis. This methodology increased the throughput of secretome analysis by 1 
order of magnitude compared to previous methodologies. 
All currently known biomarkers are secreted or shed proteins (Kulasingam V.et.al.2005), 
which makes cancer secretome analysis quite promising in biomarker research. The table 
below review the main findings from the analysis of cancer cell secretome with respect to 
identification of potential disease biomarkers. 
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Putative human cancer biomarkers identified by secretome analysis 
 
TISSUE SECRETOME. 
 
The patterns of protein secretion could be different between atherosclerotic plaques and 
normal endarteries. Thus, normal arteries and carotid endarterectomy samples (either 
complicated or fibrous) were incubated in protein-free medium and the supernatants 
subsequently analyzed by 2-DE. This approach allows the concentration of proteins 
released into the supernatant, corresponding to pathological or normal arterial wall. By 
focusing only on the secreted proteins found in the tissue culture media, there is an 
intended bias toward those molecules that would have a higher probability of later being 
found in the plasma. 
 
 
 
Schematic diagram of the experimental strategy used to harvest the proteins released by different 
artery segments. 
 
Two-dimensional electrophoresis followed by MS have enabled us to identify, in the 
secretomes, more than 80 proteins differentially expressed in complicated atherosclerotic 
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plaques versus adjacent fibrous plaques, of which 34 proteins exhibited increased release 
by complicated atherosclerotic plaques, while another 31 proteins were decreased (Duran, 
M. C.et.al 2005).  
Proteins released by the atherosclerotic plaque, as well as their classification into five 
different groups according to their function, is presented: protein transporters, structural 
proteins, metabolic enzymes, transcription factors, antioxidant, and stress defense proteins. 
Interestingly, variations in protein levels were correlated with function and an increased 
secretion of protein transporters, enzymes and signal transductors during atherosclerosis 
was observed.  
In contrast, the majority of antioxidant, stress defense and structural proteins, showed 
lower release by atherosclerotic areas than by the fibrous region (control). One of the most 
interesting proteins which showed an increased secretion in atherosclerotic plaques versus 
the control region is protein disulfide isomerase (PDI), which is considered as one of the 
major proinflammatory mediators involved in atherosclerosis (Higuchi, T..et.al 2004). 
Cathepsin D is another of the proteins which was secreted in higher levels by 
atherosclerotic plaques than in control regions. However, several isoforms were detected 
which were expressed at different levels, with increased or decreased secretion, depending 
on the considered isoform. 
Among the differentially secreted proteins, decreased heat shock protein-27 (HSP27) was 
identified as a potential marker of atherosclerosis (Martin-Ventura, J. L.et.al 2004). 
 
 
2-DE analysis of the proteins released by pathological (panels B and C) or normal (panel A) artery 
segments obtained by endarterectomy. 
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To confirm our hypothesis that plasma protein content can reflect arterial wall secretion, 
we measured soluble HSP27 level in the plasma of patients with carotid stenosis and 
healthy controls. Circulating HSP27 levels were decreased 20-fold in patients with carotid 
atherosclerosis relative to healthy subjects (Martin-Ventura, J. L.et.al 2005).  
Similar findings have been recently made in diabetic patients.  Two isoforms of HSP-27 
were identified by MALDI-MS peptide mapping, corresponding to the nonphosphorylated 
(isoform 2) and the mono-phosphorylated state of HSP-27, with Ser82 as the modified 
residue (isoform 1). Recently, both isoforms were further studied showing a significant 
decrease in atheroma plaque secretion versus the nondamaged arterial segment. The more 
acidic isoform (pI 5.65) was released at lower levels than the nonphosphorylated analogue 
in the control region. Furthermore, the intensity of the decrease in phospho- HSP-27 was 
much greater than that of the nonphosphorylated isoform in atherosclerotic plaque 
conditioned medium. Although the exact role of HSP-27 in atherosclerosis is unknown, 
previous data suggest that HSP-27 could play a protective role. This function would be 
performed not only by regulating the mobility of SMCs and coordinating actin dynamics 
within the cells, but mainly by interacting with IKK protein and inhibiting the activation of 
NF-ĸB, widely involved in plaque instability and rupture. Interestingly, all these potential 
atheroprotective functions are exerted by the phosphorylated isoform of HSP-27. In this 
sense, the decrease in HSP-27 levels, and especially the lower levels of phospho-HSP-27 
release observed in atheromatous plaques compared to controls, supports the hypothesis of 
a protective role for HSP27 against atherosclerosis.  Appearing analyze of the protein 
profiles of mammary (control) endarteries and carotid plaques by SELDI-TOF MS 
(Surface-Enhanced Laser Desorption- Ionization Time-of-Flight Mass Spectrometry) and 
again a marked reduction in the amount of HSP27 was observed in the carotid plaque 
samples.  
Identification of new biomarkers was restricted to the ability of finding and isolating new 
candidate proteins. However, in recent years, with the application of genomic and 
proteomic techniques, biomarkers can be identified without previous knowledge of their 
involvement in the pathogenesis of the disease. The list of biomarkers for atherosclerosis 
and ACS is expanding rapidly. However, the field is in the early stages of evolution and 
large-scale clinical studies are required to validate the usefulness of newly identified 
biomarkers in diagnosis, risk stratification, treatment and follow-up of cardiovascular 
diseases. 
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Chapter 3 
 
PROTEOMICS APPLIED TO STUDY PROTEIN POST 
TRANSLATIONAL MODIFICATION 
 
As already mentioned proteomics is quite useful in the study of protein posttranslational 
modification (PTM). This topics is particularly relevant because about 15 % of the human 
genes whose function is known (roughly 60% of the human genome) are engaged in signal 
transduction and communication, which takes place prevalently by PTM, particularly in 
the acute effects are taken into account. Reversible protein phosphorylation is one of the 
most abundant post translational modifications (PTM), with as much as one third of all 
proteins in a mammalian cell thought to be phosphorylated (P. Cohen 1999). The transfer 
of a phosphate group from adenosine triphosphate (ATP) to serine, threonine or tyrosine 
residues occurs through enzymes called protein kinases of which there are 518 encoded in 
the human genome.  This process is reversible and dephosphorylation occurs through a 
slightly smaller family of enzymes called protein phosphatases. This dynamic 
phosphorylation/dephosphorylation often results in the sub-stoichiometric phosphorylation 
of proteins in vivo, as only a small subset of the cellular  pool of a particular protein may 
be involved in any signal transduction cascade. The identification of sites of protein 
phosphorylation in vitro by protein kinases or in vivo, in response to various cellular 
stimuli, has been of central interest, yet presented a formidable challenge to MS based 
proteomics. One of the first routinely successful approaches combined HPLC separation of 
radiolabelled tryptic protein digests with Edman degradation and MS analysis. Two main 
kinds of phosphorylation reactions are known, those involving serine/threonine residues 
and hose related to phosphorylation of tyrosine residues by tyrosine kinases that are 
frequently associated with membrane receptors that undergo autophosphorylation triggered 
by ligand binding to generate phosphotyrosine docking sites that recruit SH2 and PTB 
domain containing proteins. The result is the assembly of large signaling complexes that 
feed receptor activity into different pathways (W.X. Schulze, et.al 2005). Specific 
techniques have been developed to investigate occurrence of phosphopeptides, by using 
specific scans on certain types of mass spectrometers. These scans are based on either the 
neutral loss of phosphoric acid from phosphoserine or phosphothreonine (neutral loss scan) 
during collision induced dissociation (CID) in positive mode, or the generation of a 
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phosphate specific reporter ion after collision induced dissociation in negative mode 
(precursor ion scan). 
 
 
 
These processes of loss of phosphate moieties do not usually occur when phosphorylation 
of peptides at tyrosine residues is considered. 
In addition to PTM by phosphorylation, proteomics techniques display potential for 
investigation of other reaction of PTM. In my guest laboratory interest in PTM is focusing 
mainly into signaling by protein oxidation and by transamidation. The former is usually 
known as Redox Proteomics. I will describe briefly this topics (although I was not 
personally involved in these experiments) because of its biologic relevance.      
 
Protein oxidation: role in signaling and detection by mass  spectrometry. 
Proteins can undergo a wide variety of oxidative post-translational modifications (oxPTM); 
while reversible modifications are thought to be relevant in physiological processes, non-
reversible oxPTM may contribute to pathological situations and disease. The oxidant is 
also important in determining the type of oxPTM, such as oxidation, chlorination or  
nitration. The best characterized oxPTMs involved in signalling modulation are partial 
oxidations of cysteine to disulfide, glutathionylated or sulfenic acid forms that can be 
reversed by thiol reductants. Some proteins regulated by cysteine oxidation, and the  
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residues and molecular mechanism involved, have been extensively studied and are well 
understood, e.g. protein tyrosine phosphatase PTP1B, MAP3 kinase ASK1 and the 
transcription factor complex Keap1–Nrf2.  
Understanding of the role oxPTMs in signalling has been facilitated by advances in 
analytical technology, in particular tandem mass spectrometry. Combinations of peptide 
sequencing by collision induced dissociation and precursor ion scanning or neutral loss to 
select for specific oxPTMs have proved very useful fodentifying oxidatively modified 
proteins and mapping the sites of oxidation.  
The oxidative PTM are not simply damaging to proteins and deleterious to cells, but under 
appropriate conditions can constitute important signalling mechanisms involved both in 
response to stress situations, such as infection and inflammation, and in normal 
physiological control of cell behavior. A variety of partially reduced oxygen species 
[superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical (OH.)], reactive 
nitrogen species [nitric oxide (NO), nitrogen dioxide (N2O) and peroxynitrite (ONOO-)] 
and reactive chlorine species (e.g. hypochlorous acid, HOCl) can be produced by 
enzymatic and chemical reactions during phagocyte activation in inflammation, most of 
which are capable of reacting with the side chains in proteins. Moreover, superoxide, 
hydrogen peroxide and nitric oxide are produced during normal metabolism, by electron 
leakage during mitochondrial respiration, redox cycling enzymes such as cytochrome 
P450, xanthine oxidase and metabolite autoxidation can all result in superoxide formation . 
Also nitric oxide is produced by nitric oxide synthases (NOS), which are either constitutive 
or inducible enzymes. No thereafter reacts with protein amino acids, leading prevalently to 
their S-nitrosylation. 
Protein oxidations at sulfur containing residues are very common oxPTMs, at cysteine 
and methionine residues. Oxidation of these residue may influence catalytic activity of 
enzymes, either directly at the active site or through conformational changes, or affect 
protein–protein interaction, protein degradation, and other post-translational modifications.  
Redox-dependent behaviour has been reported for proteins involved in most aspects of 
cellular processes: metabolism, inflammatory responses, cell proliferation and 
differentiation, survival or apoptosis, and most signaling pathways can be modulated by 
cellular redox status. These effects depend on the activation, or more commonly, 
inactivation of specific proteins, usually by reversible cysteine oxidation.  
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Cysteine oxidation and reduction are chiefly reversible events but the overall 
rearrangement in cellular metabolism are more complex events, including both reversible 
and irreversible steps, probably in relation to the final accumulation of oxidant and 
reductant levels, with glutathione playing significant roles in these processes.   
 
 
Scheme of protein thiol oxidation and regeneration reactions. 
 
Oxidation of Methionine residues can also occur and this damage can be can be repaired 
by methionine sulfoxide reductases; consequently methionine oxidation has previously 
been considered to exist as a protective mechanism for proteins, and one that in some  
proteins has comparatively little adverse on their function (Stadtman et al. 2003). Evidence 
for an additional role of certain methionines as oxidation sensors in the redox regulation of  
enzyme activity is accumulating, with particular emphasis on calcium transport and  
signaling. A notable example in human pathology is related to the susceptibility of patients  
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to cigarette smoke with development of lung emphysema in patients bearing the ZZ 
genotype of the serpin α1-Antitrypsin. Calmodulin is also very sensitive to oxidation at 
methionine residues.  
Procedures to detect oxPTM of proteins may proceed through 2D Gel based analysis for 
thiol oxidation. In these approaches proteins are usually labeled with residue or 
modification-specific reactive fluorescent chromophores (e.g. maleimide- or 
iodoacetamide-based reagent for cysteine thiols) with different colors, and then the two 
samples are mixed and run on the same gel, thus removing problems caused by variation 
between gels. Differential colour scanning is then used to detect the proteins in a technique 
known as DIGE (differential in gel electrophoresis). 
Spots of interest can be excised from the gel and the proteins identified by mass 
spectrometry, and (with luck) the site and nature of the modification might even be 
determined if the modified peptide is seen in the mass spectrometric analysis. Specific 
techniques (whose description would be outside  the scopes of this Thesis) have been 
developed for Mass spectrometric detection of disulfides and higher oxidation state sulfur, 
S-Nitrosothiols (SNOs), based either on “D electrophoresis or on LC MS approaches, as in 
the following scheme.  
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Proteomics and protein crosslinking. I will detail some more on the procedures to study 
PTM by protein crosslinking that can be investigated by combining with mass 
spectrometry for structural proteomics. Protein crosslinking can be achieved either by 
employing bifunctional reagents or alternatively enzymes that catalyze formation of 
crosslinks between distant regions in a single protein or better covalent polymers between 
different proteins. In this perspective I took advantage of Transglutaminase, that is a PTM-
ing enzyme that was the focus of years long investigations in the lab. In these cases the 
proteomic approaches can be employed not only to answer the traditional question of 
which proteins are getting crosslinked, but also to determine at which sites the protein 
crosslinking takes place. 
The location of the created cross-links imposes a distance constraint on the location of the 
respective side chains and allows drawing conclusions on the distance geometries of a 
protein or a protein complex structure (Sinz, 2003). Analysis of cross-linked peptides by 
mass spectrometry makes use of several advantages associated with MS analysis: (1) The 
mass of the protein or the protein complex under investigation is theoretically unlimited 
because it is the proteolytic peptides that are analyzed (in case a bottom-up strategy is 
employed). (2) Analysis is generally fast and, in favorable circumstances, requires only 
femtomole amounts of total protein. (3) It is possible to gain insights into three 
dimensional structures of proteins in solution and flexible regions are readily identified. (4) 
Membrane proteins and proteins that exist as mixtures of different species (post-
translational modifications, splice variants) are amenable to analysis. (5) The broad range 
of specificities available for crosslinking reagents towards certain functional groups, such 
as primary amines, sulfhydryls, or carboxylic acids, and the wide range of distances that 
different cross-linking reagents can bridge, offer the possibility to perform a wide variety 
of experiments . In these studies a first protein fragmentation step is usually performed by 
means of a protease of high specificity of cleavage (usually trypsin or V8 proteinase) and 
this might represent the main limitation of the approach since usually crosslinked proteins 
are characterized by high structural rigidity that hampers degradation by proteases. 
Several strategies have been employed to enrich crosslinker-containing species by affinity 
chromatography or to facilitate the identification of the cross-linked products; for example 
by using isotope-labeled cross-linkers or proteins, fluorogenic cross-linkers, or cleavable 
cross-linkers. 
In recently developed innovative strategies, cross-linking reactions are conducted in living 
cells by directly incorporating reactive groups into the protein, using the cell own 
biosynthetic machinery. 
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Bottom-Up Approach. 
In the bottom-up approach, the protein reaction mixture is enzymatically digested after the 
cross-linking reaction, and mass spectrometric identification of the cross-linked products is 
performed, based on the resulting proteolytic peptides. The bottom-up approach has been 
applied to map protein interfaces, but it has also proven especially valuable to determine 
low-resolution three-dimensional structures of proteins (Young et al., 2000). The most 
important prerequisite to successfully conduct crosslinking experiments is a detailed 
description of the respective amino acid sequences of the proteins under investigation. Full 
sequence coverage should be envisioned to fully characterize the protein with respect to 
possible amino acid variants, post-translational modifications, or splice variants. When 
conducting cross-linking reactions, control samples must be included, to which no cross-
linker is added, to exclude the formation of any non-specific aggregates. After the cross-
linking reaction, one-dimensional gel electrophoresis (SDS–PAGE) and MALDI-TOF 
(matrix assisted laser desorption/ionization time-of-flight) MS analysis of the reaction 
mixture can be used to check for the extent of cross-linked product formation and to 
optimize the reaction conditions. After the cross-linking reaction, there are several ways to 
isolate the cross-linked proteins from the reaction mixture. If SDS–PAGE of the cross-
linking reaction mixture is performed, the band of the cross-linked protein or the 
crosslinked protein complex is excised from the 1D-gel and subjected to enzymatic in-gel 
digestion. Alternatively, the crosslinked protein or protein complex is separated from the 
reaction mixture by size-exclusion chromatography, and the digestion is performed in the 
solution. In some occasions in-solution digestion of the cross-linked proteins was more 
efficient than in-gel digestion, where appreciable amounts of  protein can be  lost, likely is 
high molecular weight aggregates. Peptide mixtures that originated from proteolytic 
digestion of cross-linking reaction mixtures were analyzed by MALDI or ESI mass 
spectrometry. One of the inherent problems of the bottom-up strategy is that large peptides 
are commonly created from cross-linked proteins during enzymatic proteolysis due to a 
high frequency of missed cleavages. Missed cleavages occur because the most commonly 
employed cross-linking reagents react with primary amine groups at lysine residues and the  
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N-termini of proteins, and trypsin the most commonly used proteolytic enzyme will not 
cleave C-terminal to a modified lysine residue. Another limitation of the bottom-up 
approach is that cross-linked products with low charge states are frequently created during 
electrospray ionization due to a loss of positive charge after modification of the e-amino 
groups of lysine residues; that modification might cause large peptides not to be detected. 
 
 
 
General analytical strategies for protein structure characterization by chemical cross-linking and 
mass spectrometry. (A) Bottom-up approach, and (B) top-down approach using FTICR-MS. 
 
Moreover, the number of peptides with the same nominal mass but different amino acid 
sequence, increases with the rising number of amino acid residues in the peptide.  
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Top-Down Approach. 
 
One of the most direct techniques to analyze cross-linked products is the top-down 
approach, in which the cross-linked proteins are analyzed intact rather than being digested 
before the mass spectrometric analysis. Electrospray ionization-Fourier-transform ion-
cyclotron resonance (ESI-FTICR) mass spectrometry is the method of choice for this kind 
of analysis. So far, the top-down approach has been exclusively employed to determine 
low resolution three-dimensional structures of proteins from intramolecular cross-linking 
experiments. The cross-linking reaction mixture is presented to the FTICR mass 
spectrometer, and the cross-linked product is isolated in the ICR cell before it is 
interrogated with one of the various fragmentation techniques, such as sustained off-
resonance irradiation collision-induced dissociation (SORI-CID), infrared multi-photon 
dissociation (IRMPD), or electron capture dissociation (ECD). Determination of the 
accurate mass of the intact cross-linked product provides hints on the number of 
incorporated cross-linker molecules as well as on the number of modifications caused by 
partially hydrolyzed cross-linkers. The top-down approach presents some advantages over 
the bottom-up approach in that it eliminates the need to separate the reacted protein from 
the cross-linking reaction mixture before the mass spectrometric analysis, because this 
separation is accomplished by a ‘gas-phase purification’ in the mass spectrometer. Top-
down approaches have been successfully employed to assign intramolecular crosslinked 
products of bovine rhodopsin (Novak et al., 2005) as well as ubiquitin. ECD seems to be 
especially favorable in conjunction with FTICR-MS because it allows a comprehensive 
fragmentation of large peptides, while post-translational modifications are kept intact. One 
limitation of the top-down approach is that analyses of large protein assemblies are 
difficult to perform (Novak et al., 2005). That combination of bottom-up and mass 
spectrometry and top-down analysis will most likely become the strategy with the greatest 
potential for a rapid and efficient analysis of a wide variety of cross-linking reaction 
mixtures. 
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Chemical Cross-Linking in Living Systems. 
 
Several highly appealing approaches have been developed, which permit cross-linking of 
interacting proteins in their natural environment, and thus, give insight into the way 
cellular processes are organized. In one strategy reported, live cells are treated with 
formaldehyde, which rapidly permeates the cell membrane and generates cross-links 
between interacting proteins in the cell. Proteins that are cross-linked to a myc-tagged 
protein of interest are co-purified by immunoaffinity chromatography, the cross-linked 
complexes are subsequently dissociated, the bound proteins are separated by one-
dimensional gel electrophoresis and identified by tandem MS. Another intriguing strategy 
is based on the incorporation of a unique chemical into a protein of interest, using the cell’s 
own biosynthetic machinery, followed by a chemical reaction with a small-molecule probe. 
Only a handful of chemical motifs are known to possess the requisite qualities of 
biocompatibility and selective reactivity to function as chemical reporters in living cells. 
Such chemical motifs include the tetra-Cys motif that reacts selectively with biarsenicals or 
azides that react with phosphines in a Staudinger ligation or in a copper-catalyzed ‘click’ 
chemistry type reaction with alkynes (Prescher & Bertozzi, 2005). In another interesting 
study, three new photoactivatable amino acids that contain a diazirine moiety were 
designed and termed ‘‘photo-methionine’’ and ‘‘photo-leucine,’’ and ‘‘photo-isoleucine’’. 
The preference for methionine, leucine, and isoleucine implies that transmembrane 
domains as well as hydrophobic contact areas between proteins are preferentially cross-
linked. In this preference, the method is complementary to the most commonly employed 
amine-reactive chemical cross-linkers that target lysine residues and the N-termini of 
proteins. 
A major point of interest in this Thesis is the analysis of protein crosslinks formed by 
Transglutaminases (Tgases) which are widely distributed enzymes that catalyze PTM of 
proteins through isopeptide bonds which include protein cross-linking via ε-(γ-glutamyl)-
lysine bonds or  incorporation of primary amines at selected peptide bound glutamine 
residues. The cross-linked products, often of high molecular mass, are highly resistant to 
mechanical stress and to proteolytic degradation, leading to their accumulation is found in 
tissues during processes in which such properties are important, including skin, hair, blood 
clotting and wound healing. However, deregulation of enzyme activity, which is generally 
associated with major disruptions in cellular homoeostatic mechanisms,  
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explains the contribution of these enzymes to human diseases, including chronic 
neurodegeneration, neoplastic diseases, autoimmune diseases, diseases involving 
progressive tissue fibrosis and diseases related to the epidermis of the skin.  
The term transglutaminase  was first coined by (Clarke et al.,1957) to describe the 
transamidating activity observed in guinea-pig liver. Later studies  on the stabilization of 
fibrin monomers during blood clotting (Pisano et al.1968), demonstrated that 
transamidation is brought about by enzymes which cross-link proteins through an acyl-
transfer reaction between the γ-carboxamide group of peptide-bound glutamine and the ε-
amino group of peptide-bound lysine, resulting in the formation of a ε-(γ-glutamyl)-lysine 
isopeptide bond. Proteins with Tgase activity have now been found in micro-organisms, 
plants, invertebrates, amphibians, fish and birds (Griffin et al, 1992).  
In common with many other important cellular functions found in mammalian cells, 
Tgases require high concentration of Ca2+ for their activity. Moreover their Ca2+ activation 
is also modulated by further regulatory processes, which in essence means that they are 
virtually inactive under normal conditions and only activated following major disruptions 
in physiological homoeostatic mechanisms. Once activated, Tgases catalyze the formation 
of the isopeptide bonds as already described. 
Two points that deserve consideration in the case of the transamidation reaction (see the 
above schema) are the irreversibility of the reaction (some reversibility has been 
demonstrated only in the of PTM  reaction leading to protein ammine adducts) and the 
strict selectivity in the recognition of protein glutamine substrates, and poor specificity for 
the acyl-acceptor amine group, which can either be the e-amino group of peptidyl lysine or 
a low-molecular mass primary amine (frequently a polyamine). Alternatively even water 
can act as nucleophile.  
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The transamidation reactions catalyzed by Tgases. 
 
In the first instance, the products are often cross-linked high molecular-mass protein 
aggregates, while in the latter, protein-polyamine conjugates are generated, which can also 
be further polymerized. Biochemical and cell-biological studies indicate that both reactions 
involving protein cross-linking and polyamidation are relevant in vivo, and  competition 
between these amine substrates may take place within cells in a number of important 
physiological functions where they act as a ` biological glue', including that of cell death, 
cell-matrix interactions,  in the stabilization of the epidermis and of hair and in the general 
maintenance of tissue integrity.  
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Tgases  represent a family of enzymes with eight distinct Tgase isoforms as summarized in 
table below, which display appreciable degree of homology. My discussion will be 
restricted to type 2 Tgase , which is wide distributed in mammals and is the only form I 
employed in my studies.  
 
 
A point that is important to underline is the Tgase2 (which is actually a multifunctional 
enzyme, Bergamini et al, 2011)  is silent within the cell for its transamidation activity 
because it requires high concentration of calcium (above 1 mM to display appreciable 
activity) and is also inhibited by GTP. Additional levels of control of activity are 
represented by the cell oxidative power and by eventual variation in its expression.   
The structure of the enzyme is now known, as well as the general outline of its reaction 
mechanism.  
Which involves formation of thioester intermediate between the peptidylglutamine 
substrate and the thiol group  of Cys 277 that is engaged in a catalytic triad with His 335 
and Asp 358. The catalytic center is present in the core domain of the protein.  
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Backbone structure of tTgase (the picture was produced with Rasmol). Domains I-IV are coloured 
respectively in magenta, orange, blue and green ; the regulatory loop between domain II and III is 
coloured red. Amino acids involved in the active site (Cys277, His335 and Asp358), in Ca2+ binding 
(Ser449, Pro446, Glu451 and Glu452) and in interaction with GTP (Ser171, Lys173, Arg478, Val479 and 
Arg580) are coloured yellow, black and light grey respectively. 
 
The mechanism of activation of tTgase by Ca2+, mediated through the dislocation of the 
Tgase inhibitory domains, can be counteracted by the ` allosteric ' inhibitor GTP (see 
Bergamini et al, 2011 for further details). 
Since Tgase 2 is by one side a latent enzyme, by the other can catalyze protein PTM, it has 
long  been  a tempting perspective  to ascribe the physiologic roles played by the enzyme 
to its transient activation with  changes in structure and function of target proteins that 
should mediate the roles played by the protein. A point in contrast with this view is 
represented by the irreversibility of the process since in most instances studied so far, 
events of “signal  transduction” are usually related to reversible regulatory cascades. In any 
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case, this perspective stimulated interest in identifying substrate proteins (Esposito and 
Caputo, 2005) and an additional trigger for this search was represented by the possibility to 
utilize Tgase mediated formation of protein-amine adducts for biotechnological purposes 
(Porta et al, 2011). 
Although I will discuss further with this issue in the experimental section (in chapter 5 I 
will analyze the modification by Tgase 2 of some purified proteins including skeletal 
muscle troponins, brain tubulin and diphtheria toxin) it is nevertheless important to note 
that the general opinion is that Tgase 2 is kept inactive at near physiological states both in 
the intracellular and in the extracellular compartment because of its complex regulatory 
network (calcium, GTP, reductants) as detailed elsewhere (Bergamini et al, 2011). Under 
these conditions it plays a role in cell survival through its complementary activity of signal 
transduction (Johnson swiss). In contrast activation of the enzymes takes place under 
conditions of severely deranged cell homeostasis switching-on the programs leading to cell 
death, usually through apoptosis. It is exactly under these conditions that proteins in the 
extra- or in the intracellular compartments are actively modified by Tgase 2. As detailed in 
some recent review the proteins that undergo PTM by Tgase 2 in these occasions include 
mainly enzymes involved in energy metabolism, cytoskeletal proteins and stress proteins 
(Esposito and Caputo, 2005). 
Additional points of interest in Tgase research are represented by the involvement of the 
enzyme in several human important pathologic processes (Iismaa et al, 2009) which 
include: (i) autoimmune reactions as celiac disease, CD, a pathology characterized by 
hypersensitivity to dietary gliadin and development of autoantibodies directed against 
Tgase2 which also play a role in the malabsorption syndrome related to CD; (ii) 
involvement in several neurodegenerative which depend on the accumulation of 
crosslinked proteins in the brain; (iii) modulation of cell growth and programmed death 
and more generally in biology of cancer growth; and finally (iv) modulation of vascular 
responses, related to vascular remodeling in hypertension and control of permeability.  
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Chapter 4 
 
PROTEOMICS IN BIOLOGICAL AND CLINICAL APPLICATIONS  
 
From the biological point of view an immediate interest of the proteomic research is 
related to the field of modulation of protein expression through variation in their 
biosynthetic rate. This is exemplified by the issues of  Systems biology, that is the analysis 
of the relationships among the elements in a system in the response to genetic or 
environmental perturbations, with the goal of understanding the system or the emergent 
properties of the system. A system may be a few protein molecules carrying out a 
particular task (such as metabolism of galactose or any other specific metabolite); a 
complex set of proteins and other molecules physically associated or working together as a 
molecular machinery (such as the ribosome); a network of proteins operating together to 
carry out an important cellular function such as giving the cell shape (protein network), or 
a cell or group of cells carrying out particular phenotypic functions. Thus, a biological 
system may encompass molecules, cells, organs, individuals, or even ecosystems. System 
biology will continually improve our capacity to understand and to model biological 
systems on a more global and in-depth scale than ever before. The systems biology in 
medicine will be continual with the development of new technologies, which will enhance  
efficiency, scale and precision with which cellular measurements are made. This later 
influence will facilitate all aspects of health care, including the detection and monitoring of 
diseases, drug discovery, treatment evaluation, and ultimately, predictive and preventative 
medicine.  
As already pointed out a main usefulness of proteomic investigations is related to the 
analysis of qualitative/ quantitative changes in tissue protein content. These changes are 
usually ascribed to variations in the cell protein synthetic potential, but this is certainly an 
oversimplification, since several other effects might contribute to a final pattern 
documented by the experimental techniques, including chiefly protein breakdown, as in red 
blood cells. What is now clearly emerging is that - thanks to their high sensitivity and 
versatility - proteomic techniques can provide answers to complex sets of queries when 
rationally employed within an experimental design. In the perspective of biological and 
medical applications, results of proteomic experiments can be interpreted to solve  
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experimental and clinical issues. This subdivision displays certainly borderline effects and 
is therefore questionable so that we prefer to merge it somewhat in this short discussion of 
the usefulness of proteomic investigations, taking into account a few selected examples. 
A prominent field of application is that of the  
HUMAN PLASMA PROTEOME 
which has become a main goal of research in the proteomics arena. The plasma proteome 
is undoubtedly the most complex proteome in the human body; consisting not only of the 
resident transport and haemostatic proteins, but also of immunoglobulins, cytokines, 
protein hormones, secreted proteins and foreign proteins, indicative of infection. In 
addition, blood circulates through almost all tissues of the body, and therefore contains 
tissue leakage proteins, including those released from damaged or dying cells. Plasma 
should, as noted above, therefore contain information on the physiological state of all 
tissues in the body. This, combined with its accessibility makes the blood proteome 
invaluable for medical purposes. It will become possible to relate individual serum 
proteome profiles to the genome, environmental stimuli, lifestyle and aging of each 
individual. What is important to note is that plasma proteome is characterized by a wide 
dynamic range, i.e. the great difference in concentration between the most abundant and 
the trace proteins, which are difficult to identify because their presence is masked by that 
of the most abundant plasma proteins. The dynamic range of plasma proteins is on the 
order of 109, with serum albumin being most abundant (30-50 mg/mL) while low-level 
proteins are present at much lower concentrations as it is the case for interleukin-6 which is 
present at a concentration of 0-5 pg/mL. (Anderson and Anderson, 2002). The most 
meaningful subset of proteins among the entire plasma proteome to generate diagnostics 
tools should probably focus on the less abundant fraction of proteins in the blood plasma, 
as it is this fraction that best reflects tissue physiology and pathology, as these usually 
belong to the nonresident proteins that are either actively or passively released from tissue 
into the blood stream. (Liotta et.al 2003). In addition, since diseases are potentially 
associated with altered structure of plasma proteins through changes in their sugar 
components (e.g. cancer notably associated with enhanced glycosylation of proteins, and 
alcoholism with decreased glycosylation of transferrin) methods that focus on specific 
subfractions of the plasma proteome may also be useful. As proteomics techniques 
improve, the disease profiles generated should be continually related to the respective gene 
expression changes, the genome sequence information.  
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Other emerging experimental applications deal for instance with the general processes of  
 
TISSUE AND BODY AGEING  
The process of senescence for instance is characterized by wide individual variability, 
possibly under genetic control. Population genetics has widely documented major 
differences in familial  longevity in humans, encompassing brief or prolonged life 
expectancies, as originally postulated by Hayflick in his limit theory (reviewed in Hayflick, 
1985), in relation to the number of mitotic divisions in different species. If this is really the 
case it is likely that the proteomes of individuals genetically programmed for longevity 
should differ from those of subjects with constitutional short life expectancies. 
Other aspects might be related to the issues of aging in specific tissues. E.g. in muscle a 
process of sarcoplasmic atrophy associates with aging leading to an increased tendency of 
old people to fall down with risk of fractures (Ohlendieck, 2011)  In these peculiar 
instances which are not under definitive genetic control despite the known genomic 
instability in the elderly (Nyström et al  2012), it is likely that changes in the proteomes, 
that certainly take place, depend on the progressive in vivo accumulation of damage 
without appropriate repair, e.g. by unedited protein synthesis or by oxidative challenges 
(Butterfield and Dalle-Donne, 2012) in agreement with the alternative “Error catastrophe”  
theory of aging. The negative nitrogen balance in the elderly might also play a role. 
Occasionally in vivo changes may be mimicked also in vitro facilitating the investigative 
approaches. This is best observed in the case of mammalian red blood cells that have 
prolonged life spans (average half-life of 120 days in humans)  and are probably cleared 
from circulation by immunologic mechanism through recognition of a “senescence 
antigen” related to posttranslational modification of membrane Band 3 protein, along with 
release of membrane vesicles and a decline in intracellular metabolites like ATP and 2,3-
diphosphoglycerate. 
 
Thus in these perspectives also  
POSTTRANSLATIONAL PROTEIN MODIFICATIONS  
at single sites or in a more general way through effects of protein polymerization-
aggregation eventually coupled with decreased proteolysis (as they typically take place in 
the connective tissue and in organ fibrosis, or in the lens during senile cataract)  might play 
roles in physio-pathological changes in animals and humans. It is remarkable that protein  
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PostTranslational Modification (PTM) might occur both in a reversible and in an  
irreversible way. Reversible PTM – that is usually linked to signal transduction pathways – 
is more difficult to investigate by proteomic techniques because of the intrinsic instability 
of the products, such as phosphoproteins, while irreversible protein PTM, such as those 
brought about by protein proteolysis, protein oxidation or by transglutaminase mediated 
modification at glutamine residues are usually more easily managed. 
These issues have been developed more extensively in the preceding chapter. 
A special technique borderline between experimental and clinical applications of 
proteomics is  
PHARMACOPROTEOMICS. 
With this term we devise applications of proteomics in formal drug toxicology studies. As 
it is known most drugs are metabolized in the liver via the cytochrome P450 family of 
enzymes, which comprises a total number of ~200 different members, encompassing a 
wide array of overlapping specificities for different substrates. (Guengerich and Parikh 
1997). They act during phase I of drug disposal promoting (beside drug clearance from 
plasma), also its metabolism that can eventually lead to the production and removal of 
toxic species. In some instances it was possible to correlate the ability or failure to remove 
such a toxin from circulatory fluids with a specific or a subgroup of P450 proteins. Each 
individual person will have a slightly different P450 profile, largely from polymorphisms 
and changes in expression levels, although other genetic and environmental factors aside 
from P450 also need to be taken into consideration (Vermes et.al, 1997). The marked 
variation of individuals in their ability to clear a compound can be one of the key factors in 
deciding the overall pharmacokinetic profile of a drug. Not only will this have a bearing on 
the likelihood of a patient responding to a treatment, but it will also be a factor in 
determining the possibility of experiencing an adverse effect and is also requirement to 
judge the drug half life and thereby its correct dosage. 
In the case of the Pharmaproteomics approach for drug development, for instance animals  
can be dosed with increasing levels of an experimental drug over time, and serum samples 
can be drawn for consecutive proteome analyses. Using this procedure, it should be 
possible to identify individual markers, or clusters thereof, that are dose related and 
correlate with the emergence and severity of toxicity. Markers might appear in the serum at 
a defined drug dose and time that are predictive of early toxicity within certain organs and 
if allowed to continue will have damaging consequences. These serum markers could  
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subsequently be used to predict the response of each individual and allow tailoring of 
therapy whereby optimal efficacy is achieved without adverse side effects being apparent. 
This application can obviously extend to tracking toxicity of drugs in clinical trials where 
serum can be readily drawn and analyzed.  
A relevant example in the field of proteomics applied to clinical pharmacology is 
represented by studies on OGT719. This is a novel galactosyl derivative of the cytotoxic 
agent 5-fluorouracil (5-FU), which is currently being developed for the treatment of 
hepatocellular carcinoma and colorectal metastases localized in the liver. The premise 
underpinning the design and rationale of OGT719 was to derive a 5-FU prodrug capable of 
targeting, and being retained in cells bearing the asialoglycoprotein receptor (ASGP-r), 
including hepatocytes, hepatoma Huh7 cells  and some colorectal tumour cells. The growth 
of the human hepatoma cell line Huh7 is inhibited by either 5-FU or OGT719. If the 
inhibition by OGT719 were the result of uptake and conversion to 5-FU as the active 
component, then it would be expected that Huh7 cells would show similar proteome 
profiles following exposure of the cancer cell line to either drug, as depicted in the 
following figure 
Additional relevant information might be provided by comparing the proteomes of cells in 
which the drug target has been eliminated by molecular knockout techniques, or by 
treatment with small molecule inhibitors believed to act specifically on the same target. 
 
Proteins that are specifically up- or down-regulated in Huh7 cells by either 5-fluorouracil (5-FU) or 
OGT719: (a) elongation factor 1α2, (b) novel (three peptides by MS-MS) and (c) α-subunit of 
prolyl-4-hydroxylase. Arrows indicate up- or downregulated. 
 
An even wider range of studies deals with proteomic research directed to management of  
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CLINICALLY RELEVANT PATHOLOGIES  
In most instances these studies deal with plasma and/or specific tissue proteome in relation 
to the classic goals of Clinical Biochemistry, to identify and measure the concentration of 
proteins useful  in diagnosis and in assessment of prognosis, clinical course, response to 
therapy and risk of  recurrence. This is particularly true in the case of chronic diseases, 
notably for cardiovascular and neoplastic diseases for which plasma proteome is the 
preferred research medium to investigate the presence of proteins whose “altered” levels 
correlate with the disease processes. Most importantly the results of threes investigations 
require to be clinically validated, i.e. the relevance of the identified proteins as disease 
biomarkers must correlate with clinical assessments.  Improvements in the resolution, 
sensitivity, and mass accuracy of mass analyzers, an increase in the sample size used as the 
initial training set, and the combined use of multiple SELDI chip surfaces can all be 
expected to improve the specificity and predictive value of this approach. This technique 
can be used along with any number of other indicators such as genetic defects, or 
histopathologic findings, to make more accurate diagnoses. In any case, the initial findings 
using this method are encouraging, and to generate mass spectra requires only a small 
volume of serum and is relatively fast, taking as little as 30 min (Petricoin.E.F.et.al 2002).  
Equally encouraging is the opportunity to apply this approach to a broad spectrum of 
diseases. In this regard, a proteome “signature” has already been developed to discriminate 
individuals with prostate cancer from healthy individuals (Petricoin et al,  2002). The 
method of serum proteome pattern generation more comprehensively exploits the 
information contained within the serum proteome compared to single molecule 
identification, and the approach exploits a major characteristics of complex diseases, 
namely, that there is a whole cohort of molecular changes ranging from different protein 
levels to changes in protein cleavage and other modifications. 
The concept behind this diagnostic approach is that the blood plasma proteome reflects 
tissue and organ pathology, causing patterns of protein changes that have diagnostic 
potential without even knowing the identities of the individual proteins. Since MS-based 
approaches provide a pattern of peaks, the idea is that these patterns can discriminate 
certain diseases and that this diagnostics involving the pattern or “signature” of the 
proteins rather than their identities might improve their clinical relevance (Petricoin and 
Liotta, 2004). To apply this approach, researchers have taken advantage of surface  
enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) 
analyzing for proteome diagnostic pattern samples of serum from affected and unaffected  
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patients individually applied to a matrix with analysis of retained proteins that are 
subsequently ionized and detected by TOF-MS. New computer-based artificial intelligence 
algorithms were used to identify patterns among a “training set” of mass spectral data, 
generated by SELDI-TOF-MS, for instance in the case of  ovarian cancers. The algorithm 
generated a proteomic pattern that was then used to identify ovarian cancer in individuals 
from a second independent group individuals, some of whom were affected. In this 
instance the positive predictive value of the approach was 94%, the specificity was 95%, 
and the sensitivity was 100% .  
In more general terms the rational of these studies is to compare the pattern of proteins 
release from the pathologic lesion into the blood stream to identify proteins which are 
landmarks of the disease either because of their unique features or thanks to variations in 
their levels in plasma. 
Once their identity is achieved and their relevance is established in clinical validation 
studies they can likely supplement clinical assessment by classic routine immunologic 
analyses. This issue is virtually the same that was applied for detection of classic cancer 
biomarkers and newly discovered proteins will likely suffer the same limits of classic 
biomarkers, since they will probably be indicative more or organ of the lesion rather than 
of the lesion itself. Actually no true cancer biomarker really exists, although a few (PSA, 
ferritin and CA 125) tend to approach this goal. In any case classic as well as newly 
developed biomarkers are not themselves useful as diagnosis but are better employed for 
follow-up patients after effective therapy (levels of circulating markers should drop-down 
after therapy with a clearance kinetics reflecting their half-life in vivo) or to monitor local 
or systemic recurrence of the disease. In addition it must be appreciated that the rise of 
serum biomarkers might involve not only molecules directly released from pathologic 
lesions but also moieties reactive against the lesion as a result of its presence or possibly 
with the teleological role to limit its spreading. This is the case of cancer autoantibodies 
(Murphy et al, 2012).  
Although, as already indicated, identification of temptative biomarkers usually proceeds 
through analysis of the plasma proteome of affected/unaffected individuals, there are also 
additional approaches. Among them it is important to recall those dealing with patterns of 
direct comparative protein analysis or of the secretome. In the direct comparison portions 
of both the lesion and of surrounding normal tissue are homogenized and extracted and 
their protein abundance is estimated by direct inspection in 2D gels or by techniques of 
fluorescence merging after the proteins in the normal tissue and the lesion are labeled by  
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different fluorophores. In the secretome approach (that begins to find wide application also  
in the field of cardiovascular diseases, see below for a more detailed description) the 
lesions are incubated for short periods of time in primary culture, usually without 
supplementation of serum, and the secretome the proteins that are secreted by the lesion  
(including also molecules that are shed from the surface) are collected for analysis, since 
they should mimic the release of proteins in vivo from the lesion. Proteins of secretome 
play a key role in cell signaling, communication and migration. The need for developing 
more effective cancer biomarkers and therapeutic modalities has led to the study of cancer 
cell secretome as a means to identify and characterize diagnostic and prognostic markers 
and potential drug and therapeutic targets. In addition, extracellular matrix components and 
other molecules secreted by tumor cells are a rich source of potential markers and drug 
targets for cancer treatment (May, 2009). Secreted proteins are also most likely excellent 
candidate serological tumor markers as they are released by the cells thus having highest 
possibility to enter the circulation (Kulasingam V, Diamandis EP 2008).  
Analysis of secreted proteins is quite challenging; this may be attributed to technical 
difficulties such as a) presence of the proteins at frequently low concentrations due to their  
high dilution (in body fluids or cell culture media), b) their masking and contamination by 
cytoplasmic or other normally non secreted proteins released following cell lysis and 
death, and c) masking by serum proteins (i.e. fetal bovine serum) normally present in the 
culture media. These issues underscore the importance of procedures that have to be 
followed for cell culture and conditioned medium (CM) collection so as to avoid 
contamination from dead cells and cytosolic proteins as well as for effective protein 
concentration, regardless the protein separation technology in use.) 
A drawback in the secretome approach is represented by possible tissue damage because of 
hypoxia during the time interval between surgery/biopsy and laboratory procedures. This 
time lapse could variably associate with cell necrosis or apoptosis so that the collected 
proteins might not belong to the secretome but to intracellular proteins released through 
damaged membranes. 
Proteomic techniques have found wide applications also in the search of  
NOVEL CARDIOVASCULAR BIOMARKERS  
particularly in relation to Atherosclerosis the pathology resulting coronary heart disease 
and stroke, that represent the most common cause of death in developed countries. 
Atherosclerosis is an inflammatory process that results in the development of complex 
lesions or plaques, containing lipids that protrude into the arterial lumen. Therapeutic  
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programs have been developed (largely on the bases of the Framingham study) to check 
factors that promote development of atherosclerosis with the aim to limit its incidence and 
adequate biomarkers are available for this primary prevention. In contract major problems 
still in relation to assessment of the evolution of  the atherosclerotic plaques, that may be 
two-sides leading to plaque remodeling (that means formation of an endothelial and fibrous 
cap that separating the lipid and inflammatory core of the lesion from the blood stream, 
protecting from additional damage) or the plaque instability and rupture that  
 
 
 
proceeds through plaque ulceration and subsequently thrombosis resulting in the acute 
clinical complications of myocardial infarction (MI) and stroke, as represented 
schematically in the picture above, that shows the Arterial wall (composed of three layers: 
the intima, the innermost layer lined with endothelial cells (ECs) on the luminal side; the 
media, consisting of several layers of smooth muscle cells (SMCs) and the adventitia, 
which mainly consists of connective tissue) and the subendothelial wall invasion by 
oxidized LDL protein leading to inflammation and lesions of the upper layers. 
Thus atherosclerosis is now looked at as a form of chronic inflammation resulting from 
interaction between lipoproteins (oxidized LDL; oxLDL), monocytes/macrophages, T 
lymphocytes, and the normal cellular elements of the arterial wall. This inflammatory 
process leads to the development of complex lesions or plaques that protrude into the  
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arterial lumen (Aikawa and Libby, 2004). It has been shown that endothelial cells (EC), 
upon activation, express adhesion molecules, that favor the attachment of monocytes 
which migrate into the subendothelial space and differentiate into macrophage. Uptake of 
oxLDL by these macrophages, via scavenger receptors (SR-A, CD36), leads to formation 
of foam cells and cytokines secreted by lymphocytes and macrophages, attract smooth 
muscle cells (SMC) which secrete extracellular matrix proteins forming the fibrous cap. 
Macrophages and SMC cell death by apoptosis or necrosis induced by a combination of 
injuries (oxLDL, proteolytic environment, etc.) leads to the formation of a necrotic core 
and accumulation of extracellular cholesterol. Secretion of matrix metalloproteinases 
(MMPs) and cathepsins by macrophages weaken the fibrous cap, favoring plaque rupture. 
This is dangerous because it exposes prothrombotic molecules as tissue factor, platelet 
adhesive matrix molecules to the blood, induce the formation of a thrombus, and elicit an 
acute coronary syndrome  (Ruggeri, 2002). Therefore, plaque composition rather than the 
degree of arterial stenosis predicts the probability of rupture: large, fibrotic lesions can be 
relatively stable. In contrast, plaque rupture frequently occurs in relatively minor but lipid 
rich lesions with marked inflammatory infiltrates. 
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Chapter 5 
 
 
TRANSGLUTAMINASE AND SITE SPECIFIC PROTEIN 
MODIFICATION.   
 
GENERAL CONSIDERATIONS 
 
As summarized before Transglutaminases (Tgases) have been for several years a main 
focus of research in the laboratory (Griffin et al, 2002; Bergamini et al, 2011), with 
particular emphasis on a specific isoform, Tgase 2, which is considered a multifunctional 
protein involved in (i) protein PTM at glutamine residues through isopeptide bonds with 
low molecular weight amines (transamidation) or epsilon amino groups of lysine residues 
in other proteins (protein crosslinkage); (ii) intracellular transduction of external signals 
acting as a G-protein with GTP/GDP cycling; and (iii) as scaffold for the assembly of 
structural protein in the extracellular matrix (ECM) (Bergamini et al, 2011). 
Details in the reciprocate regulation of the transamidase and signalling have already been 
provided. Just to summarize the Tgase crosslinking activity is considered silent in normal 
conditions inside the cells because calcium levels are very low (in the micromolar  range) 
and GTP levels are elevated, thus allowing normal cellular life span. Indeed phases of 
massive activation of Tgase 2 in the intracellular compartment have been associated with 
waves of apoptosis, along with proein PTM through isopeptide bonds which are resistant to  
degradation unless Tgase 2 in involved acting in the back reaction, which has been proved 
to occur only in the case of substrate proteins couplped with low molecular weight amines, 
not in protein crosslinkage.  
In the present section I will consider Tgase 2 as an enzyme active in PTM at specific sites 
and analyze its reaction looking particularly at the identification of the glutamine residues 
targeted for modification, in proteins whose structure is known. The model protein chosen 
for these investigations are the muscle Troponin complex (that was already known to be a 
substrate of Tgase 2, but its exact site of modification had not been previously determined) 
(Bergamini et al, 1995; Gorza et al, 1996); brain tubulin - which is a prominent protein of 
cell cytoskeleton – was taken into account because cytoskeletal proteins are frequently 
preferred substrates of Tgases (Esposito and Caputo, 2005) and the CRM 197 mutant of 
the Diphteria toxin (DT). The choice of this last protein derives from an observation we 
obtained several years ago in experiments that were carried out in collaboration with 
colleagues at the ISI, because of the interest in DT as a vaccine and a drug for the specific  
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killing of neoplastic cells, upon targeting with cell specific ligands. The present 
experiments were carried out for safety reasons with the non toxic mutant CRM197 
bearing the  amino acid substitution E52G that inactivates the ADPribosylating activity 
without disrupting the basic structural properties of the protein. 
The experiments on troponin T have already been published (Squerzanti et al, 2013) while 
those on the other proteins Tubulin and DT are in advancement but yet complete.  
 
OUTLINE OF THE GENERAL PROCEDURES EMPLOYED FOR THE EXPERIMENTS OF PROTEIN 
LABELLING IN VITRO BY HUMAN TGASE 
 
Tgase was purified from outdated human erythrocyte by a method developed in our 
laboratory which consists of lysis of the erythrocytes, adsorption and elution from DEAE-
cellulose, PEG  fractionation, and subsequent chromatography on DEAE sepharose and on 
heparin sepharose (Gambetti et al., 2005). The enzyme is homogeneous and can be stored 
at – 20°C in 20% glycerol without appreciable loss of activity for at least one year, after re-
activation of the enzyme by treatment with DTT. Activity is assayed by a filter paper 
procedure recording incorporation at timed intervals of radioactive putrescine (Gambetti et 
al., 2005) or continuously of fluorescent dansylcadaverine into a standard suitable protein 
acceptor as dimethylcasein (Curtis and Lorand 1976), or the test protein as reported in each 
experiment. For the fluorescent assays excitation and emission wavelengths were  360 nm 
and 546 nm.   
Troponin was isolated from rabbit muscle ether powders by the procedure of Potter (1982) 
while Tubulin (devoid of MAPs that were separated by chromatography on cellulose-
phosphate) was purified from fresh porcine brain according Williams and Lee (1982), 
respectively. Stabilization of tubulin in the assembled and disassembled states was 
achieved by thermal cycling (Lee and Timasheff, 1975). The mutant Diphtheria toxin 
CRM 197 was a kind gift of Dr. Rino Rappuoli, from Novartis, Siena.   
Incubations for incorporation of probe amines into the selected substrate proteins were 
carried out as detailed in the description of the experiments dealing with the specific 
protein. At the required time intervals  samples of the native and of the labelled proteins 
were submitted to standard SDS-PAGE and the gel stained with colloidal Coomassie blue, 
a staining solution that does not interfere with the MS proteomic analysis, to identify 
labelled proteins (eventually evidenced by fluorescence staining under UV light), excise 
the band and digesting them with either trypsin or V8 proteinase, as reported in the specific  
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method section of the Troponin T investigation. The peptides released from the digests of 
the native protein and of the protein labelled with Spermine or with Dansyl-cadaverine 
were submitted to MALDI TOF and the peptides with differing m/z ratios were further 
submitted to MS/MS after ionization-induced fragmentation, to precisely identify the site 
of labelling. The identification of the residues labelled in the involved peptides can be 
achieved by applying the Mascot software as described elsewhere in this thesis.  
 
STUDIES WITH TROPONINS.  
 
Aim of the study 
 
Troponins play relevant roles in the physiological regulation of contractility of skeletal and 
cardiac muscle and in monitoring of pathologic changes in muscles. From the 
physiological point of view they control calcium sensitivity and regulate the onset of 
filament sliding. These effects are brought about by modulation during ontogenesis of 
expression of different isoforms generated by alternative splicing of individual troponin 
subunits and by modification in PTM of troponins usually by phosphorylation. Both 
Troponin I and troponin T contribute to these regulatory effects  (Toyota et al 2008; 
Oliveira et al 2012). From the pathologic point of view, assay of circulatory levels of cTnT 
and cTnI are relevant in monitoring and in diagnosis of cardiac damage, usually but not 
constantly due to ischemic attacks. Investigations on perfused hearts submitted to hypoxic 
stress (Gorza et al, 1996) revealed previously that immunoreactivity of Troponins was 
modified and that PTM of these proteins involved not only phosphorylation but also 
calcium dependent proteolysis and polymerization that was due to activation of Tgase 2.   
The occurrence of this PTM in an in situ system and its relevance in cardiac physiology 
and pathology and eventually in molecular diagnostic in CV diseases prompted us to 
investigate in more detail the effects of Tgase 2 on muscle troponins. 
Results of these studies have been published and the text of the paper is reproduced below.   
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Comments to the study on Troponin labelling 
 
A significant aim of our research on protein labelling by human Tgase is the elucidation of 
the rules that dictate substrate recognition by the enzyme. As mentioned rules of 
recognition of glutamine residues are very selective while those for the acyl-acceptor are 
very flexible so that both primary amines (either amino groups in proteins or soluble low 
molecular weight amines, as well) can act on thio-ester catalytic intermediate. The data we 
have obtained in the present investigation indicate that the modified glutamine 13 is 
located in the N-terminal region and that the flanking sequence is particularly reach in 
acidic side chains because of clustering of glutamic acid residues.  
In any case it is likely that this is not the only parameter relevant for the selection of 
substrate glutamine residues since Q13 in TnT is present in a flexible region, as it happens 
also for other proteins that are glutamine substrate of both microbial and eukaryotic 
Tgases. Actually, it is also because of our interest in these mechanisms of substrate 
recognition that we decided to expand this section of the research, as it is demonstrated 
below by the studies on labelling of tubulin ands of DT, that are described below. 
The second point that deserves some comments is related to the possibility that Troponin 
undergoes  
PTM by Tgase in living cells and to the possible functional consequences of this 
modification. Previous experiments demonstrated that this PTM may occur in the beating 
perfused heart since forms of TnT with high molecular weight consistent with the 
formation of dimers or even larger aggregates are detectable in Western blot of ischemic 
myocardial cytosol mostly if undergoing “calcium paradox” and stunning. What instead is 
not known is if polyamines, which are considered physiologic or para-physiologic Tgase 
substrates (Folk et al, 1980), may play any role in this perspective. The issue of cardiac 
polyamine metabolism has been already the object of investigation but not been so much 
explored in the perspective of ischemic/riperfusion injury damage, while data are available 
in relation to the pressure induced damage (e.g. Cetrullo et al, 2011), under conditions in 
which cardiac overload is known to affect expression of Tgase 2 (Iwai et al, 1995;Small et 
al, 1999; Nanda et al, 2001; Deasy et al, 2013). This is certainly an important topics and 
further studies are required to delineate completely its relevance beyond the present feeling 
of a general protective action of polyamines.  
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STUDIES WITH TUBULINS.  
  
General aspects 
 
Microtubules, largely composed of tubulin and associated proteins, exist in the cell cytosol 
as two main populations, that of the true microtubules which are the thickest cell filaments 
present at relatively stable levels in the inter-mitotic phase contributing to maintenance of 
cell shape and that of tubules of the mitotic spindles which are assembled in cells entering 
the mitosis employing also tubulin released from disassembled cytosolic microtubules (de 
Forges et al, 2012). In addition tubulin based cables contribute to cell trafficking of 
vesicles and organelles (Garnham and Roll-Mecak,  2012). This apparent stability of inter-
mitotic microtubules is actually a dynamic effect (it is also called “dynamic instability”) 
and arises from the contemporaneous occurrence of processes of assembly-disassembly at 
the extremities with different polarity of the microtubules. Posttranslational modifications 
(acetylation, phosphorylation, glutamylation, tyrosylation, etc) of tubulin in vivo by a 
number of enzymes and interaction of the microtubules with microtubule-associated-
proteins (MAPs) are important processes in determining the relative size of cellular tubulin 
pools (Hammond et al. 2008).    
As already remembered many proteins of the cytoskeleton are efficient Tgase substrates 
(Griffin et al, 2002; Esposito and Caputo, 2005). This observation and a formal similarity 
between the cycling mechanisms of assembly/disassembly of the microtubules and the 
actin microfilaments suggested us to investigate whether also brain tubulin might be an 
efficient substrate for Tgase 2 in vitro and to investigate in detail the conditions and the 
sites of labelling, employing chiefly proteomic approaches to obtain this important 
information. Indeed our results confirm these assumptions proving in particular that (i) 
Tgase 2  catalyzes incorporation of radioactive/fluorescent amines into tubulin and 
conjugation of tubulin itself with model glutamine peptide substrates; (ii) neither 
disassembled tubulin nor polymerized tubulin filaments are involved in formation of 
crosslinks most likely because of three dimensional hindrance between reactive side 
chains, despite a more efficient incorporation of the fluorescent label dansylcadaverine into 
polymerized than depolymerised tubulin; (iii) incorporation of primary amines occurs at 
multiple glutamine residues in subunit β, prevalently at several positions, at the C-terminal 
end of the peptide;  (iv) aggregated (“polymerized”) is more effective than disassembled 
tubulin in the incorporation of amine probes at glutamine residues.  
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EXPERIMENTAL PROCEDURES  
 
To investigate modification of brain tubulin, the protein (1–2 mg/ ml) was incubated with 
purified Tgase 2, 5 mM calcium and 1 mM spermine or o.2 mM Dansylcadaverine as 
specified. Stoichiometry of glutamine labelling was checked measuring incorporation of 
radioactive putrescine into the tubulin protein by a filter paper assay (Bergamini et al. 
1995). To identify the targeted glutamine residues incubations carried out in the presence 
of cold spermine or dansylcadaverine were terminated by boiling and the tubulin subunits 
were resolved by standard SDS-PAGE. Relevant bands in gels stained with colloidal 
Coomassie blue were excised, the proteins submitted to tryptic digestion in situ, and the 
peptide mass analysed by MALDI TOF and MALDI TOF–TOF techniques, as described 
for the labelling of muscle troponins. As we encountered difficulties in the analysis of 
labelled tubulin by this approach of in situ proteolytic digestion, also digestion in solution 
was carried out. 
When searching for reactive lysine residues we have employed as probe the peptidyl-
glutamine analogue Cbz-Gln-Gly, in experiments similar to those aimed to identify 
reactive glutamine residues.  In this case bands in gel were processed by digestion with V8 
proteinase and further processed as for tryptic peptides. 
 
RESULTS 
 
Labelling of glutamine and lysine residues in tubulin  
 
I will employ the term monomeric tubulin to identify the complex of two α,β subunits in 
the unpolymerized form of tubulin. To incorporation of primary amines into brain tubulin 
was checked by incubating tubulin (1-2 mg/ml) with Tgase 2, in the presence of 5 mM 
calcium and either 0.5 mM radioactive putrescine or dansylcadaverine (which is 
fluorescent). Both radioactive and fluorescent assays were performed on the aggregated 
tubulin form (see Figure 5.1, in which data of the assay of incorporation of radioactive 
putrescine are presented as a function of time of incubation employing as substrates 
tubulin, Dyphtheria toxin and dimethylcasein as a model substrate). The data clearly 
demonstrate that both proteins tubulin and DT are glutamine substrates of Tgase 2, 
although incorporation levels are clearly lower than those obtained with dimethylated 
casein. Assays of tubulin labelling were also carried out by the continuous fluorimetric 
assay that was performed on both polymerized and depolymerised tubulin by changing the 
temperature in the instrument cell, verifying it by recording turbidity at 350 nm.  The 
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incorporation of radioactive putrescine (Fig. 5.1) yielded an apparent stoichiometry of 4 
amine groups for monomer,  
 
 
while the fluorescence assay confirmed effective incorporation of the probe and suggested 
in addition significantly higher labelling in tubulin assembled in filaments as compared to 
free disaggregated monomeric tubulin (Figure 5.2). 
 
 
The analysis of the pattern of fluorescent labelling of tubulin in SDS denaturing 
electrophoresis demonstrated that the glutamine residues recognized as substrates by Tgase 
2 are contained mostly if not exclusively in the  β  subunit, although very faint 
fluorescence is present also in higher aggregates and on the top of the stacking gel, because  
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of some form of major insolubility of the product (see Fig. 5.3). 
MS spectroscopy analysis of the peptide released of gel fragments containing the tubulin 
subunits labelled with Dansylcadaverine that had been resolved by SDS-PAGE yielded a 
consistent coverage  of the sequence of both subunits (over 80% of the sequence was 
covered) but we did not succeed in resolving the structure of the C-terminal region by in 
gel proteolysis with trypsin of the tubulin monomer labelled either with spermine or 
dansyl-cadaverine. This failure is probably dependent on poor ionizability of the C-
terminal region, which likely is the labelled one because it is rich in glutamine residues. To 
overcome these difficulties we have already performed additional experiments in which 
proteomic search of the incorporated labels was performed both by MALDI-TOF analysis 
of peptides released by in gel proteolysis with V8 proteinase and by in solution proteolysis 
followed by ESI mass spectroscopy. Results are still in progress and will be the object of a 
future report. 
In future studies it will be important to explore the nucleating ability of modified tubulin 
and the regular occurrence of thermal cycling for the conversion between the disaggregated 
and the aggregated states in polyamine modified tubulin as well. 
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Comments on the studies with tubulin 
 
Our investigation with tubulin prove definitely that also this cytoskeletal protein is labelled 
by Tgase 2, but failed up to now to identify the exact site of labelling, in contrast with the 
relatively straight forward analysis of the labelling of TnT. This clearly demonstrates that 
the procedures of analysis must be must be carefully fitted to the experimental problem 
under investigation taking into account the properties of the protein that is employed in the 
labelling experiments.  
Besides their interest at the light of the features of Tgase 2 as a protein modifying enzyme, 
these data wait for clarification for their functional interest (if any) at the light both of 
polyamines as physiologic substrate of Tgases and the general roles of polyamines as 
regulators of cell growth (Folk at al, 1980) and differentiation (Wallace, 2009).  
Another point which clearly deserves investigation in this optics is represented by an 
analysis of transamidation of tubulin by polyamines in relation to the 
polymerization/depolymerization cycling and to the in vivo labelling of tubulin by 
polyamines as a novel PTM of this protein. This could be looked at more likely by analysis 
of the effects of increased calcium availability in the intracellular compartments of cell 
depleted or enriched with polyamines.  
 
STUDIES WITH DIPHTHERIA TOXIN  
General aspects 
Diphteria toxin (DT) is a highly cytotoxic toxin produced by Corynebacterium diphtheriae 
as a monomeric single chain pro-toxin of 535 amino acids, that is cleaved by proteinases to 
the active toxin containing two fragments (A-B), further linked by a disulphide bridge. The 
N-terminal region (fragment A of 193 amino acids in the proteolyzed DT) is the catalytic C 
domain, i.e. the region toxic to the eukaryotic cells, while the remaining 342 amino acids 
in the C-terminal moiety contain two domains T and R that are involved in membrane 
translocation (T domain) of the C domain and in Receptor-mediated (R domain) anchorage  
to target cells, usually through heparin binding EGF receptors. DT is highly toxic bringing 
about death of host cells by blocking the protein biosynthesis machinery through inhibition 
of eukaryotic Elongation Factor 2 (eEF2). The inhibition is mediated by ADP ribosylation 
of histidine residues of eEF2 to the so-called diphtamide residues by the catalytically 
active domain C of the toxin after internalization. (Collier, 2001).  
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 Fig. 5.4 The domain structure of the diphtheria toxin 
 
Several features that have attracted interest of researchers in DT, include (i) its 
involvement in the pathogenesis of diphtheria; (ii) the mode of action as an effective 
blocker of protein synthesis; (iii) the availability of toxin mutants that retain immunogenic 
activity but are devoid of toxicity (including CRM 197, see below); (iv) the possibility to 
employ the T-R domains as a vehicle of peptides to the intracellular space (just like 
penetratin) and (v) the possibility to employ the catalytic C domain as a highly efficient 
weapon against cancerous cells, with various biotechnologic pharmaceutical applications. 
Thus the isolated domains of DT are suitable to be exploited by genetic manipulation to 
generate fusion proteins either between the translocating T-B moiety and appropriate 
therapeutic peptides (e.g. antibodies or  cytokines fragments) or through fusion of the toxic 
A domain with ligands targeting cell-specific receptors, particularly for therapy of 
leukemias and lymphomas, sparing normal cells (Frankel et al, 2000; FitzGerald et al, 
2004). 
Since, as mentioned, we had proved previously in unpublished experiments that DT is a 
substrate of Tgase 2, we found of interest to evaluate the possibility to conjugate DT with 
carriers by the simple enzymatic procedure of treatment with Tgase with peptides, low 
molecular weight chemicals (e.g. drugs) or polymers (such as PEG) that might alter in vivo 
half-life (Fontana et al, 2008) or with peptides that might direct it to specific targets.  
In this preliminary research I investigated the properties of DT as substrate of Tgase 2 with  
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aim to localize the sites of labelling as a prerequisite for specific coupling strategies. The 
studies have been carried out with the non toxic DT variant CRM 197 for the safe of the 
investigators since this mutants largely maintains the structure of the wild type toxin 
(Malito et al, 2012). At this purpose I wish to recall that the available mutants of DT have 
been obtained using the mutagenesis with        N - methyl - N' - nitro - N – 
nitrosoguanidine, generating toxins whose functionality was altered but showed cross- 
reactivity with polyclonal antibodies anti – DT. These " Cross -reacting material" (CRM) 
can be divided into two groups depending on alterations in the fragment B with the 
function of  receptor binding and translocation (CRM 30, 45, 228, 107, 102, 103, 9 and 
1001) or in fragment A with impaired enzymatic activity (CRM 197, 228 and 176). 
CRM197 presents the substitution G52E, i.e. replacement of glycine 52 with glutamic acid, 
that prevents binding of the cofactor NAD+ with almost complete loss of catalytic activity 
(Giannini et al., 1984).  
 
EXPERIMENTAL METHODS 
 
Modification of  CRM 197 by Tgase 2 was carried essentially by the same general 
procedures outlined above at concentrations of DT between 0.2 and 0.5 mg/ml,  in the 
presence of Tgase 2, Dansylcadaverine (or spermine, or Carboxybenzoyl-QG) and 5mM 
CaCl2,  monitoring the progress of the reaction by fluorescence assay (λex 340 and λem 
546), by radioactive incorporation of by electrophoretic analysis of protein polymerization. 
Procedure for proteomic analysis have been already described. 
 
RESULTS  
 
Initial attempts to screen CRM 197 as substrate of type 2 Tgase involved incorporation of 
radioactive or fluorescent amines  into the protein, thus acting as Q substrate. The results 
of the radiochemical assay (using putrescine as the incorporated probe) demonstrated that 
CRM 197 is an appreciable glutamine substrate for tissue Tgase (see Fig 5.1, above) and 
were confirmed with the fluorescent assay, displaying time-dependent increase in the 
intensity of fluorescence emission at 546 nm increased in a time dependent way in 
incubations containing Tgase, CRM 197, and dansylcadaverine as the fluorescent probe. 
All these results therefore agree that some glutamine residues of CRM 197 are recognized 
as substrate by mammalian Tgase (results not shown). 
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A minimal stoichiometry of labelling was provided by incorporation of radioactive 
putrescine in the filter paper assay, with an apparent value slightly higher than one 
mole/mole despite the possible availability of free lysine residues that might compete with 
the exogenous amine as acyl-acceptors of the reactive glutamine residue(s). The 
contemporaneous occurrence of protein crosslinkage competing with the incorporation of 
external amines is likely as shown by progressive accumulation of high molecular mass 
protein aggregates which failed to enter the separation gel along the time of incubation as 
proved by SDS gel electrophoresis (Fig.5.5). This clearly suggests an aggregation of CRM 
197 occurring through formation of γ-glutamyl-ε-lysine isopeptide bonds. As expected 
addition of amine (spermine) or glutamine (Cbz-QG) exogenous substrates inhibit protein 
crosslinkage (see also figure 3)    
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5 Electrophoretic separation of DT by SDS-PAGE. A. Diphtheria Toxin. B. Crosslinking between 
DT and Tg-ase after 30 minutes of incubation. C. DT with Tg-ase and spermine after 30 minutes. D. DT with 
Tg-ase and spermine after 120 minutes. E. Crosslinking between DT, Tg-ase and spermine after 30 minutes 
of incubation. F. Crosslinking between DT, Tg-ase and spermine after 120 minutes of incubation. 
 
We searched further for the specific sites of glutamine and lysine labelling within the 
sequence of CRM 197. For this issue we resolved electrophoretically incubation mixtures 
containing Tgase, calcium and either spermine or Cbz-QG  to isolate the band of residual 
monomeric toxin, which presumably was at least partially labelled  by the probes at 
selectively label glutamine and lysine residues of the toxin. In all instances bands were 
excised from the gel  and submitted to proteomic analysis after peptide chain 
fragmentation in situ by treatment with trypsin. 
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The MS analysis of these data is still in progress. 
 
 
References 
 
Bergamini CM, Signorini M, Barbato R, Menabò R, Di Lisa F, Gorza L, Beninati S. (1995) 
Transglutaminase-catalyzed polymerization of troponin in vitro. Biochem Biophys Res 
Commun. 206: 201-206. 
 
Bergamini CM, Collighan RJ, Wang Z, Griffin M. (2011) Structure and regulation of type 
2 transglutaminase in relation to its physiological functions and pathological roles. Adv 
Enzymol Relat Areas Mol Biol. 78: 1-46.   
 
Cetrullo S, Tantini B, Facchini A, Pignatti C, Stefanelli C, Caldarera CM, Flamigni F. 
(2011) A pro-survival effect of polyamine depletion on norepinephrine-mediated apoptosis 
in cardiac cells: role of signaling enzymes. Amino Acids. 40: 1127-1137 
 
Collier RJ. (2001) Understanding the mode of action of diphtheria toxin: a perspective on 
progress during the 20th century. Toxicon. 39: 1793-1803. 
 
Curtis CG, Lorand L. (1976) Fibrin-stabilizing factor (factor XIII). Methods Enzymol. 45: 
177-191 
 
Deasey S, Shanmugasundaram S, Nurminskaya M. (2013) Tissue-specific responses to 
loss of transglutaminase 2. Amino Acids. 44: 179-187 
 
de Forges H, Bouissou A, Perez F (2012) Interplay between microtubule dynamics and 
intracellular organization. Int J Biochem Cell Biol. 44: 266-274 
 
Esposito C, Caputo I. (2005) Mammalian transglutaminases. Identification of substrates as 
a key to physiological function and physiopathological relevance. FEBS J. 272:  615-631  
 
FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. (2004) Recombinant 
immunotoxins for treating cancer. Int J Med Microbiol. 293: 577-582. 
 
Folk JE, Park MH, Chung SI, Schrode J, Lester EP, Cooper HL. (1980) Polyamines as 
physiological substrates for transglutaminases. J Biol Chem. 255: 3695-3700 
 
Fontana A, Spolaore B, Mero A, Veronese FM. (2008) Site-specific modification and 
PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv 
Rev. 60: 13-28. 
 
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, 
Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. (2000) Diphtheria toxin 
fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. 
Leukemia. 14: 576-585. 
 
 
80 
 
Gambetti S, Dondi A, Cervellati C, Squerzanti M, Pansini FS, Bergamini CM. (2005) 
Interaction with heparin protects tissue transglutaminase against inactivation by heating 
and by proteolysis. Biochimie. 87: 551-555.  
 
Garnham CP, Roll-Mecak A. (2012) The chemical complexity of cellular microtubules: 
tubulin post-translational modification enzymes and their roles in tuning microtubule 
functions. Cytoskeleton  69: 442-463 
 
Giannini G, Rappuoli R, Ratti G. (1984) The amino-acid sequence of two non-toxic 
mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 12: 4063-4069. 
 
Gorza L, Menabò R, Vitadello M, Bergamini CM, Di Lisa F. (1996) Cardiomyocyte 
troponin T immunoreactivity is modified by cross-linking resulting from intracellular 
calcium overload. Circulation 93: 1896-1904 
 
Griffin M, Casadio R, Bergamini CM. (2002) Transglutaminases: nature's biological glues. 
Biochem J. 368: 377-396 
 
Hammond JW, Cai D, Verhey KJ. (2008) Tubulin modifications and their cellular 
functions. Curr Opin Cell Biol. 20, 71-76   
 
Iismaa SE, Mearns BM, Lorand L, Graham RM.  (2009) Transglutaminases and disease: 
lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 
89: 991-1023 
 
Iwai N, Shimoike H, Kinoshita M.  (1995) Genes up-regulated in hypertrophied ventricle. 
Biochem Biophys Res Commun. 209: 527-534. 
 
Lee JC & Timasheff SN. (1975) The reconstitution of microtubules from purified calf 
brain tubulin. 
Biochemistry. 14: 5183-5187 
 
Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, Biancucci M, 
Brock A, Berti F, Bottomley MJ, Nissum M, Costantino P, Rappuoli R, Spraggon G. 
(2012) Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc 
Natl Acad Sci U S A.  109: 5229-5234 
 
Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. (2001) Targeted 
inactivation of Gh/tissue transglutaminase II. J Biol Chem. 276: 20673-20678 
 
Oliveira SM, Zhang YH, Solis RS, Isackson H, Bellahcene M, Yavari A, Pinter K, Davies 
JK, Ge Y, Ashrafian H, Walker JW, Carling D, Watkins H, Casadei B, Redwood C. (2012) 
AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of 
murine ventricular myocytes. Circ Res. 110: 1192-1201 
 
Pappenheimer AM Jr.  (1977) Diphtheria toxin. Annu Rev Biochem. 46: 69-94. 
 
 
 
81 
 
Potter JD (1982) Preparation of troponin and its subunits. Methods Enzymol 85B: 241–263  
 
Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, Dorn GW 2nd, Liggett SB. 
(1999) Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique 
hypertrophy phenotype independent of phospholipase C activation. J Biol Chem. 274: 
21291-21296 
 
Squerzanti M, Cervellati C, Ura B, Mischiati C, Pucci P, Annunziata S, Iannone C, 
Casadio R, Bergamini CM, Esposito C. (2013) The side chain of glutamine 13 is the acyl-
donor amino acid modified by type 2 transglutaminase in subunit T of the native rabbit 
skeletal muscle troponin complex. Amino Acids. 44: 227-234 
 
Toyota N, Takano-Ohmuro H, Yoshida LS, Araki M, Yoshinobu K, Suzuki-Toyota F.  
(2008) Suppression of cardiac troponin T induces reduction of contractility and structural 
disorganization in chicken cardiomyocytes. Cell Struct Funct. 33: 193-201 
 
Wallace HM. (2009) The polyamines: past, present and future. Essays Biochem. 46: 1-9 
 
Williams RC Jr, & Lee JC. (1982) Preparation of tubulin from brain. Methods Enzymol. 85 
Pt B, 376-385 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
Chapter 6 
 
Experimental Investigations: Oncologic studies 
 
Proteomics is emerging as an important field of investigation for almost every clinical 
issue. There are several relevant examples – as mentioned in the introductory chapters in 
this thesis – but the most relevant applications are those related to severe chronic diseases 
as cancer and cardiovascular diseases (CVD), which are at the same time frequent causes 
of morbidity and mortality. In the case of CVD, for instance proteomics is increasingly 
applied (White and Van Eyk, 2007) to assess difficult clinical entities as staging chronic 
heart failure (CHF) and risk stratification for atherosclerotic disease, in relation to the so-
called “stability” of the atherosclerotic plaque i.e. its relative tendency to the formation of a 
fibrous cap and re-endothelization (the favourable evolution) or the formation of 
superficial ulcers that might progress towards thrombosis and formation of emboli, the 
usual cause of acute coronary syndrome and of stroke, depending on the affected arterial 
branch (Blanco-Colio et al 2009). The aim is that of the discovery of novel biomarkers of 
disease/risk for their clinical validation through analysis of the plasma proteome or 
eventually of the secretome of cultured vessels, since secretome is the pathway by which 
cells (in this case vascular cells) release specific proteins in the circulating blood stream 
(Kullo and Cooper, 2010). The close contact between vascular layering cells and plasma 
makes these approaches particularly attractive in the field of cardiovascular diseases. 
Besides the field of CVD, major applications of clinical proteomics arise from the study of 
malignant tumours, again for selecting  novel specific biomarkers for direct clinical 
application for tumour staging in terms of prognosis and of response to clinical therapy or 
of markers of basic biologic behaviour. In relation to direct clinical use, novel biomarkers 
are expected to perform better as guide-lines in patients stratification particularly in 
selection of adequate therapeutic protocols as for the sensitivity to radiotherapy by analysis 
of serum proteome (Cowan and Vera, 2008; Scaife et al, 2011) or chemotherapy through 
expression of MDR protein (Zheng et al, 2010) eventually by immunohistochemistry in the 
pathologic lesions or other markers in draining fluids (Kuang et al, 2012). Also tissues 
might be analyzed. In his perspective it is notable that data on experimental animals 
demonstrated tissue specific responses in gene expression (Lim et al, 2011). An interesting 
and important case in humans is represented by the triple negative phenotype in breast 
tumours, i.e. the negativity for E2R, PgR and HER-2 (human epithelial growth factor 
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receptor-2) that accounts for more roughly 15% of total cases and poses great problems for 
its resistance to specific tailored therapies, as I will discuss further below. Notably present 
proteomics research is expanding utility of tumour markers also to cancer for which 
markers haven’t yet been discovered and validated as for instance renal cell cancer (Craven 
et al, 2012).  
In addition to these clinically oriented applications, appropriate careful applications of 
proteomics deal with the defining new emerging concepts in modern oncologic biology, 
those of cancer stem cells and of the conversion of epithelial-like into mesenchymal-like 
cells, the so-called EMT (Epithelial Mesenchimal Transition) and its reverse MET. These 
processes probably/frequently  associate with vascular invasion and metastasis by the 
haematic rather than lymphatic routes, and with the onset of resistance to chemotherapy, as 
well as with the additional concept of the cancer stem cells. At the same time proteomic 
analysis of tissues from animals submitted the experimental radiation injury revealed 
possible involvement of EMT in the pathogenesis of radiation induced lung fibrosis 
(Almeida et al, 2013) a clinically relevant complication in patients undergoing thoracic 
radiation for malignancies. 
  
DISCOVERY OF NOVEL PERFORMING CANCER BIOMARKERS BY PROTEOMICS.  
THE CASE OF  THE INFILTRATING DUCT CARCINOMA OF THE BREAST 
 
During the years, starting from the beginning of the ‘40ies last century, with the 
investigations of alkaline and acid phosphatase in patients affected by prostate and by 
biliary tract carcinomas, there has been raising interested in the release of tumour related 
molecules in the blood stream. In many instances, particularly in the earliest time of 
investigation, these were enzymes but later on also carbohydrates, mucins, onco-fetal 
antigens, hormones have been taken into account (Chan et al, 2006). What is now 
emerging is that in most cases these substances, that are improperly designed as tumours 
biomarkers, should not be considered as indicative of the type of pathology but rather – at 
best – as indicative of the affected tissue. The only cancer biomarkers to which a relatively 
confidence can be warranted particularly for population screening is PSA, the prostate 
specific antigen, a form of kallikrein that is commonly present in prostatic secretion and 
increases in the blood stream in the case of metastatic prostate adenocarcinoma, and 
possibly α-fetoprotein for screening of hepatocellular carcinoma in regions of high 
endemic frequency. In other words cancer biomarkers are not reliable for cancer diagnosis  
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and their use should best be related to screening  and more properly in assessing 
effectiveness of initial antineoplastic therapy of whatever kind or in monitoring for 
recurrencies.  An additional perspective for which determination of specific cancer 
biomarkers has found application is the estimation of sensitivity of tissues to therapeutic 
interventions particularly in the case of hormone dependent cancers, like prostate, breast 
and endometrial cancer.  A notable example is the Triple Null phenotype in breast cancer 
which is an aggressive and therapy resistant form, characterized by the lack of expression 
of E2R, PgR and HER-2. 
These limitations further stimulate interest in genetic markers as indicative of the 
occurrence of specific mutations in the tumours, that are related to the pathogenesis of the 
lesions, such as B-Raf mutations (the amino acid substitution V600E) in papillary thyroid 
cancer (PTC) (Xing 2012) or the expression of specific proteins isoforms as cytokeratins 
and SCCA (Squamous Cell Carcinoma Antigen)  in HNSCC, the common cancer of the 
oral cavity, pharynx and larynx (Chan et al, 2006). These markers are commonly 
determined on biopsy or surgical specimens by immuno-histochemical techniques.  
Among the techniques that might be applied to the search of novel potential circulatory 
biomarkers (plasma is clearly the preferred biologic source to search because it can easily 
be obtained with minimal traumatism) interest is now increasing in the secretomic 
approaches (Stastna and Van Eyk, 2012) or in direct comparison between protein 
expression patterns in normal and pathologic tissues obtained from single patients by 
classic proteomic methodologies. 
We have investigated in this topics employing the last approach of direct tissue comparison 
in a population of patients affected by infiltrating ductal adenocarcimas of the breast. The 
text that has been accepted for publication on Mol. Med. Reports is reproduced below.    
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Abstract 
 
We have analyzed by comparative 2D proteomics the protein composition of ductal breast cancer 
and surrounding normal tissue in single patients to detect candidate disease biomarkers for 
diagnosis and prognosis. Chaperonins and cytoskeletal proteins predominate among the 11 
proteins for which we detected major changes in abundance. In addition a few cytokeratins are 
also altered but they however cannot serve as specific circulatory biomarkers. The likely 
physiopathologic roles of these proteins are discussed.  
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Introduction  
With incidence of about one million new cases/year breast cancer (BC) is a major cause of death in 
women diagnosed at the stage of infiltrating disease [1]. BCs are classically classified as 
lobular/ductal forms, with scirrhous, medullary and mucinous variants. Their biologic-clinical 
heterogeneity and variable response to therapy lead to refined classifications based on receptor 
status [2] as luminal A and B type (ER positive);  HER2 type over-expressing EGF receptors; basal 
type (not expressing ER, PR and HER, also known as triple negative, TNBC) and normal-like cancer. 
Attempts to additional typing are based on  markers   for diagnosis and prognosis (cytokeratines 
and chaperonins), in relation to specific mutations detected by proteomic and cDNA microarrays 
approaches [3]. Interesting investigations are in progress.  
Here we present proteomic analysis of normal and BC tissue from individual patients undergoing 
mastectomy at the Ferrara University Hospital, during the last 2 years. Changes in expression of 
selective proteins in most patients supports the search for their roles as tissue and serological 
markers for identification of aggressive tumors and  as targets for therapy refractory cases. 
 
Materials and Methods 
Tissue Specimens 
Samples of normal and cancer tissue were collected from 28 patients (indicated as P1 to P28) with 
ductal BC for proteomic investigation approved by the institutional ethical committee. Diagnosis 
was confirmed by histopathology, which proved that tumor specimens contained more than 50% 
tumor cells. Samples from 10 patients providing large amounts of tissues were snap-frozen in 
liquid N2 and stored at -80°C until proteomic analysis for the present investigation. 
Proteomics by 2D electrophoresis and mass spectrometry 
Proteomics on BC and normal tissue from the same patient was performed by homogenization in 
2.5 volumes of 7 M urea, 2 M thiourea, 4% CHAPS, 40 mM Tris, 1mM benzamidine, 1mM 
iodacetamide, 1mM EDTA, pH 8.8. After centrifugation, portions of supernatant corresponding to 
260 µg protein, were submitted to IEF on precast pH 3-10 linear IPG strips at 40000 volts.h, 
according to manufacturer’s instructions.  After thiol reduction by 1% DTT and alkylation by  4% 
iodoacetamide, strips were submitted to 2
nd
 dimension SDS-PAGE on 12,5%c polyacrylamide gels 
for 1 hour at 200V. Gels were stained by colloidal Coomassie, scanned with Molecular Imager 
Pharos FX Systems  and analyzed by the  ProteomeWeaver 4 program (Biorad). Spots excised from  
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the gel were processed by trypsin digestion for MS peptide identification. Briefly, gel fragments 
were rinsed in buffered acetonitrile, and dried. After additional thiol group reduction and 
alkylation, peptides were digested overnight with 12.5 ng/µl trypsin, resuspended in aqueous 
formic acid and analyzed with Ultimate 3000 Nano/micro HPLC apparatus Coupled with a LTQ-
Orbitrap XL mass spectrometer [4,5]. By means of Excalibur 2.0.7 software spectra were submitted 
for peptides identification to the MASCOT program against the NCBI database.  
Results 
In Table 1 we summarize clinical characteristics of the patients along with the list of proteins with 
altered expression recognized by 2-DE proteomics. We achieved optimal resolution with total load 
of 260 μg of proteins  on the IEF strip, running second dimension electrophoresis at constant 
voltage of 200 V for 1 hour, to avoid proteins smaller than 20 kDa to run out of the gel.  Typically 
2D electrophoresis of tumor and normal  samples in single patients (Figure 1) resolved several 
hundreds proteins. By visual inspection 11 proteins had altered expression in BC tissue (circles, 
Figure 1), 2 proteins with lower and 9 higher levels of expression. These proteins were identified by 
MS spectroscopy. The nine proteins with increased expression (Table 1) are endoplasmin precursor 
(gp96), protein disulfide isomerase (PDI), TCP-1 subunit theta (TCP1-θ), F actin-capping protein 
subunit β (FACP-β), heat shock protein beta 1 (namely, HSP27), triosephosphate isomerase (TPI), 
RS/DJ-1, beta-tubulin (Tub-β) and beta-actin (Act-β) while carbonic anhydrase 1 (CA-1) and A-FABP 
(Adipocyte fatty acid binding-protein) are down-regulated. These proteins thus include molecular 
chaperones, cytoskeletal proteins and metabolic enzymes. We have identified also several 
cytokeratin peptides but we ignored them because of possible contaminations during sample 
processing. Actually  cytokeratins are relevant in BC immunocytochemical approaches but not 
when searching for circulating biomarker discovery [6]. 
Estimation of abundance of proteins with altered expression was achieved through normalization 
of intensity of spots from different gels against a virtual spot calculated as average on the same 
gel of 5-6 spots with identical expression in all analyzed samples, obtaining ratios of protein 
present in spots of BC and corresponding normal tissue in 2-DE gels (Table1). Ratios larger than 2 
or smaller than 0.5 denote proteins significantly more/less expressed in BC versus normal tissue. 
Thus gp96 and TPI proteins were consistently modulated in at least 7 out of 10 patients, even if the 
score for TPI should be higher because its expression was not constantly detectable in normal 
tissue making impossible to calculate a precise ratio. PDI, FACP-β, Tub-β were highly expressed in 8 
out of 10 tumors. HSP27, RS/DJ-1, CA-1 and A-FABP were consistently modulated in 9 out of 10 
patients. Act-β and TCP1-θ were always  elevated in all tumors we analyzed. 
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Discussion 
We resolved numerous proteins in normal and cancerous breast, 11 displaying consistently altered 
expression in tumors.  The proteins with increased expression are 
i) chaperonins, which are notably involved in increased tumorigenicity, metastatic potential and 
resistance to chemotherapy. They include HSP27 induced under unfavorable conditions to protect 
cells from death, preventing aggregation of denatured proteins, regulating caspase activity, 
intracellular redox state, polymerization of actin and cytoskeletal dynamics [7]; HSP27 is a 
proposed  immunocytochemical discriminator to refine C3 and C4 categories in suspect BC 
aspirates [8]; and gp96 of the HSP 90 family [9] which represents a tool for active immunization 
against tumors by associating with cell surface peptides for presentation to cytolytic T lymphocytes 
and cell destruction. Notably Vitespen, a peptide vaccine based on gp96, prolongs survival in 
patients with early stage melanoma or renal  cancer [10]. The presence of gp96 in infiltrating 
ductal BC is attractive for vaccine treatment in TNBC patients resistant to classic therapy while 
maintaining expression of gp 96 (see patient P20). 
 ii) the cytoskeletal proteins Act-β, FACP-β, Tub-β and TCP1-θ. The last protein assists ATP-
dependent folding of actin and tubulin [11]. Interestingly some cytoskeletal proteins upregulated in 
BC are involved in estrogen receptor activation: Act-β binds to the ER α complex, contributing to ER 
nuclear functions [12]; chaperonin TCP1-θ (spot 3) is involved in folding Act-β [13] and estrogen-
regulated HSP27 controls palmitoylation of ER, required for its interaction with membranes [14]. 
This indicates that cytoskeletal rearrangement as a key step in the motility mechanisms for 
metastatic spreading, but might also be involved in hormone receptivity [15].  
iii) signaling proteins with altered expression are RS/DJ-1, TPI and A-FABP. RS/DJ-1 is an oncogene 
protein regulating RNA-protein interaction, present in sera from BC patients but not healthy 
subjects along with circulating antibodies against this protein [16]. Similarly, autoantibodies 
against TPI are present in BC patients [17] but also in patients with oral cavity and lung squamous 
cell carcinoma [18,19]. PDI catalyzes formation/ rearrangement of protein disulfide bonds, acting 
as a reductase at cell surface cleaving disulfide bonds with structural modifications of cell 
associated proteins and as chaperonin (inhibiting aggregation of misfolded proteins) or 
antichaperonin (facilitating aggregation) inside cells, depending on concentration. In addition PDI 
binds estrogen and thyroid hormones [20]. Interestingly, knockdown of PDI in BC MCF7 cells 
induces caspases-dependent apoptosis [21]. A-FABP is another protein whose expression is 
affected in a declining mode. It plays roles in intracellular lipid transport and metabolism, and 
signalling. Prognostic value for A-FABP was reported in bladder cancer since a decreased 
expression  
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correlated with poor prognosis [22]. It is induced by PPAR ligands (the promoter region of the A-
FABP gene contains functional peroxisome-proliferator-responsive elements [23]) and its 
overexpression is likely beneficial in treatment of bladder cancer. Contrasting results are reported 
in BC since serum levels of A-FABP associate with tumor risk and aggressive behavior [24], but 
comparable values of expression were reported in ductal infiltrating carcinoma and normal tissue 
[25]. Our data document instead decreased levels of A-FABP in ductal BC than normal tissues in 
9/10 patients, including the TNBC patient in our population. The association between BC and A-
FABP and the possible selective induction by PPAR ligands might impact in strategies for therapy of 
TNBC if the data will be confirmed in larger populations. 
In conclusion, despite the limited number of subjects  investigated in the present study, the 
robustness  of our findings suggests they might be also observed in future larger studies that 
include others kind of tumors and their multidrug resistant counterparts. This is an aspect of 
particular interest, since one of the problems of conventional anti-cancer therapy is the 
development of drug resistance. The proteins for which we documented an altered expression in 
the infiltrating ductal BC could be exploited as novel targets for therapeutic interventions or 
represent novel diagnostic/prognostic markers for early detection of aggressive tumors, 
particularly those with MDR phenotypes, in early  stages of disease. 
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Figure and Table captions 
 
Figure 1. Two-dimensional gel electrophoresis of mammary tissue proteins. Total proteins from 
homogenates of tumor or normal breast tissues from the same patient were loaded onto each gel 
and separated by two-dimensional gel electrophoresis. The spots circled in the image, representing 
the relevant up or down-regulated proteins, were excised and analyzed by LC-MS/MS. The 
identified proteins are listed in Table 1. 
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Table1. 
Table1. Population characteristics and identification of expression levels of proteins significantly 
altered in BC. Ratios of expression of individual proteins in normal and BC tissue is defined in the 
text. Underlined values indicate patients where expression deviates from the general trend 
observed in our cases 
Case P10 P13 P18 P19 P20 P21 P22 P23 P27 P28 
Clinical Setting 
Citolo
gy 
pT1c-
pN0(i)(sn) 
pT2- 
pN0(i-
)(sn) 
pT1c-
pN0(i+)(sn) 
pT1c- 
pN0(i-
)(sn) 
pT1mic-
pN0(i-
)(sn) 
pT2-
pN1a 
pT1c-
pN0(i+)(s
n) 
pT1c- 
pN0(i-
)(sn) 
pT1c- 
pN0(i-
)(sn) 
pT2-
pN3a 
NCI n.d. 4.5 3.3 3.32 n.d. 5.56 3.28 3.3 3.24 6.44 
Grade G2 G3 G2 G2 micro G3 G2 G2 G2 G3 
ER 90 0 96 97 0 21 99 72 99 52 
PR 50 0 36 94 0 8 98 64 56 68 
HER2 1+ 1+ 0 0 0 0 0 0 0 3+ 
Identified proteins 
GP96 2,43 2,00 4,86 8,13 5,00 4,67 1,14 5,00 1,27 1,18 
PDI 8,25 3.38 6.00 4.33 n.d. 9.33 2 4.76 n.d. 4.55 
TCP1-
θ 
2.22 2.00 2.11 4.33 2.89 7.19 4.80 12.68 3.86 5.38 
FACP-
β 
3.50 1.44 2.75 2.00 2.00 2.92 1.30 3.33 2.89 2.00 
HSP27 2,43 1,29 5,33 6,77 2,57 2,00 2,29 4,67 3,60 2,73 
TPI 3,50 n.d. 5,75 2,41 1,38 3,50 n.d. 3,33 6,00 3,93 
RS/DJ 
1 
2,25 0,91 4,00 2,53 3,58 2,33 2,80 4,80 6,00 2,42 
TUB-β 2,53 1,40 6,50 2,00 2,02 3,50 0,80 4,98 4,32 2,18 
ACT-β 6,25 3,60 8,00 2,28 2,75 3,89 2,00 13,33 3,52 3,64 
CA-1 0,50 0,28 1,11 0,50 0,50 0,18 0,50 0,19 0,50 0,45 
A-
FABP 
0,23 0,18 0,50 0,11 0,25 0,13 0,36 0,89 0,15 0,18 
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PROTEOMICS AND ADVANCES IN CANCER BIOLOGY. THE EMT CONCEPT 
 
A main novel concept in relation to cancer biology is that of the occurrence of EMT. This 
is a relatively recent notion related to the capacity of cancer cells to reprogram their 
differentiation, in the sense of conversion of epithelial into mesenchymal cells. The former 
ones are characterized by  close cell-cell adhesions that limit cell mobility through protein-
protein interactions, while mesenchymal like cells are devoid of cell adhesive molecules 
and rather expressing at high levels proteinases which favour their mobility. During the 
transition there a overlapping progressive processes of loss of biomarkers of the epithelial 
cell and gradual acquisition of biomarkers of a mesenchymal phenotype. Among the 
stimuli that favour the EMT, cytokines play major roles, (notably TGFβ) with possible 
involvement of bone marrow derived cells, but also mechanical stimuli might contribute as 
it happens in the EMT in the cholangiocarcinomas cell lines that we have analyzed. I will 
come again to these concepts below along with the analysis of proteins differentially 
expressed in tumours undergoing EMT. 
EMT has been recognized to play a role in several physiologically and pathologically 
relevant processes as outlined by Thiery et al, (2009). Kalluri and Weinberg (2009) have 
defined types of EMT. Type 1 plays a role in the prenatal development in which cells from 
the embryonic surface leaflets move deeply into the mesenchymal region to migrate and 
contribute to organ development. This process is not associated with inflammatory stimuli, 
which are instead present in type 2 EMT, which is associated with would healing with 
epithelial cells that converse into the mesenchymal ones for space filling during would 
healing by second intention repair. At the last extreme is type 3 EMT, that occurring in 
cancer tissues, in which dedifferentiated mesenchymal cells find easier access to blood 
vessels to spread the tumour by blood borne metastases, rather than by the lymphatic route. 
Besides its dedifferentiation and the acquisition of markers of cell mobility and of ECM 
degradation, EMT in cancer tissues is characterized by appearance of distinct phenomena 
in vitro in cultured cells, notably by formation of large globular cells aggregates commonly 
known as spheroids.  
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Fig. 6.1 Schematic view of the processes of type 1, type 2 and type 3 EMT. 
 
 
Type 3 EMT is likely to contribute considerably to the heterogeneous appearance of poorly 
differentiated cancer, a feature which has been ascribed to either occurrence of EMT or 
also to an intrinsic property of tumours themselves considered as aggregates of 
differentiated and of poorly differentiated cancer cells that have a definitely higher ability 
to invade and to metastatize. These cells have therefore been described alternatively as 
products of EMT or as cancer stems cells to indicate their high intrinsic capacity to 
reproduce the tumour at distant sites. In this perspective differences in regulation and 
protein expression in lesions of primary tumours and in metastatic foci are easily 
understandable. At least in some tumours as for instance ovarian tumours spreading within 
the peritoneal cavity as ascites tumours (Shao et al, 2009) both the processes of acquisition 
of resistance to classic chemotherapy (or even to radiotherapy) and the secondary 
localization as coelomatic metastases are events associated with EMT (Zhang et al, 2008) 
as well as with the enhanced catalytic activity of type 2 Tgase.  
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For a few types of cancers, investigations of differential protein expression have already 
been published in lesions exhibiting epithelial phenotype or evidence of EMT, by either 
immuno-cytochemistry or proteomic profiling, employing several experimental systems, as 
exposition to TGFβ or comparison between primary tumours and metastatic lymph nodes 
which should be enriched in cancer cells that have undergone EMT, as noted above. This 
information is available for instance for HNSCC, prostate, pancreatic and lung cancer and 
expression of several proteins is frequently affected in a major way. Significant differences 
have been found in expression of cytokeratins, cadherins (particularly E-cadherin and 
fibronectin), MMPs, and focal adhesion kinases (Mathias and Simpson, 2009). 
At our knowledge this kinds of investigations have never been carried out in the 
adenocarcinomas of the bile tract, tumours that are characterized by a high level of 
invasiveness. For this reason we decided to investigate this clinical entity, employing as 
models the cell lines SK-ChA-1 and MZ-ChA-1 to verify whether alterations in the protein 
expression pattern resemble those observed in other types of tumours, also because these 
cholangio-carcinomas cell lines are able to undergo EMT induction by simple mechanical 
stress as culturing under appropriate stirring conditions (Roncoroni et al, 2008), assuming a 
appearance of “spheroid” multicellular aggregates. These simple stimuli have not been 
reported as inducers of type 3 EMT in other cancer models. 
 
 
EXPERIMENTAL STUDIES ON THE SPHEROID PHENOTYPE OF CHOLANGIOCARCINOMA 
CELLS 
 
Introduction 
 
Cholangiocarcinomas are tumours originating from the epithelial cuboidal or columnar 
cells lining the surface of the bile ducts and account for 3% of all the gastrointestinal 
tumours. They can arise in the gallbladder, the hepatic and the common duct, the 
intraduodenal portion of the common duct or even the intrahepatic bile ducts roots. 
Cholangiocarcinoma is diagnosed with difficulty since the  symptoms are rather aspecific 
(abdominal pain, jaundice, digestive disturbances, itching, laboratory signs of cholestasis) 
and arise late, making surgery suitable only in a limited number of patients, despite the 
critical location usually permits detection of the tumours when they are still low in size. 
Since both radiotherapy and traditional chemotherapy (5-fluorouracil and gemcitabine 
alone or in combination with cisplatin) showed disappointing results in terms of survival in 
unoperable patients, the development of new therapies is badly needed (Khan et al, 2005).  
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These considerations led us to explore the possibility of the occurrence of EMT in two 
models of  cholangiocarcinoma, the cell lines SK- Cha-1 and MZ-Cha-1 that was originally 
supplied by prof. Alexander Knuth (Ludwig Institute, Frankfurt, Germany) and cultured 
for us by colleagues at the Gastroenterology and Celiac Disease Research Unit (Drs. 
Roncoroni, Elli and Bardella) of the Ospedale Maggiore Medical Polyclinic, University of 
Milan.  
These cells were cultured under two different experimental settings to obtain either Two-
Dimensional (2D) or Three Dimensional (3D) cultures (which are also called multicellular 
tumour spheroids). In the 2D setting cultures of SK-ChA-1 cells were grown in Dulbecco’s 
modified Eagle’s medium  supplemented with 1% penicillin 100 U/ml, streptomycin 100 
mg/ml, 2% L-glutamine 200mM and 10% foetal bovine serum in a humidified  5% CO2 
incubator at 37 °C, in six-well tissue culture plates. In the Three-Dimensional culture 
approach (that to obtain multicellular tumour spheroids or MCTSs) growth was started by 
seeding 2.105 cells/ml in 15 ml of complete Iscove modified Dulbecco’s medium 
(supplemented with antibiotics and glutamine as above) in polycarbonate Erlenmeyer 
flasks and incubated in a gyratory rotation incubator (60 rev/min) at 37 °C in an air 
atmosphere. Homotypical aggregations became visible after 4 days of culture and  MCTSs 
were usually complete within 7 days (mean diameter_standard deviation, 270 ± 53.5 µm). 
Cells obtained by 2D and 3D were collected by centrifugation and lysed by treatment with 
TUC 2-D lysis buffer (7 M Urea, 2 M thiourea, 4% CHAPS, 40mM TRIS) and a cocktail 
of protease inhibitors.  For 1  million cells we used 130µl of lysis buffer.  After protein 
determination by the method of Bradford 300 µg of protein were loaded onto a 3-10 NL 
IPG strip 7 cm (Biorad), that was focused for 12 hours until reach  the maximum voltage 
of 4000V, to obtain a total 60000 volt h. After thiol reduction by 1% DTT and alkylation 
by  4% iodoacetamide. The second dimension was run on a slab polyacrylamide gel 
(12,5%) at 200 volts, until the bromophenol reached  the bottom of the gel to avoid loss of 
small MW peptides.  In the case of the 3D spheroids lysis was performed with 150 µl of 
lysis buffer and the protein load was assayed only by the protein determination assay. After 
fixing the gels washed 2 times with bidistilated water and stained with colloidal 
Coomassie, scanned with Molecular Imager Pharos FX Systems  and analyzed by the  
ProteomeWeaver 4 program (Biorad). 
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The above picture are those of the Cells of SK-ChA1 cell line growing as adherent pre-
confluent cells in resting flasks (upper picture) and of cells of the same cell line growing as 
spheroids under continuous stirring (Courtesy of Dr. Leda Roncoroni, University of Milan, 
see the text for details). 
Cells at these stages of growth have been employed in our experiments of bidimensional 
electrophoresis to evidence eventual alterations in the protein expression patterns.  
Relevant gels reported below display protein expression patterns in the confluent cultures 
(left panel) and in the spheroid growing phenotype (right panel) of the MZ cell line (this 
page) 
 
               
 
and the SK cell line 
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Although minor differences apparently exist in the protein expression levels between the 
two MZ and SK cell lines are evident (compare for instance the left panels), in both 
instances significant differences in the expression pattern appear as the cultures are grown 
under conditions of confluence or multicellular spheroid phenotype. The regions that 
appear to be most affected are those at pH 5 and at pH 7 to 8 (Note that the acid and the 
basic pH are on the left and the right side in each gel).   
A few proteins that are differently expressed have been identified and submitted to 
proteome analysis to identify them on the basis of their sequence. Mass spectroscopy 
identification is in progress.  
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FINAL REMARKS 
 
 
 
During the tenure of the PhD fellowship my main duty was to implement the use of 
proteomics in my guest laboratory, and to apply proteomic techniques to basic biological 
topics as well as to clinically relevant issues both in diagnostic and in investigative 
perspectives.  
Thus I was not ascribed a single research time but rather the development of the technique 
and the optimization of its applications in relation to the scientific equipment available at 
the unit, which is suitable for proteomic investigations by the bi-dimensional 
electrophoresis approach to isolate specific proteins under investigation.  
The final steps of the analysis consisted in the identification either of precise sites of 
labelling in irreversible protein PTM by Tgase 2 or of proteins involved in specific issues 
in oncology, i.e. in the altered protein expression in transformed cells that might be chosen 
as cancer biomarkers (in this case in breast ductal adenocarcinoma) and in 
cholangiocarcinoma cells undergoing EMT in vitro. This final analytic problems were 
performed for us by collaboration between our laboratory and the CRIBI Biotechnology 
Centre at the University of Padoa as well as the CEINGE Centre for Genetic Engineering 
at the University of Naples. I thank deeply these colleagues, who helped in my research. 
The outmost competence of these centres in mass spectroscopy is well recognized and was 
instrumental for our – still limited - success. However - as I explained - the analysis of the 
data is still in progress, mainly because of the busy activity in these host centres and 
therefore their  time limitations. Data for additional publications will certainly be available 
as soon as these analyses will be completed. 
Coming back to the experimental plans and to the applications of proteomics to the 
solution of  the research queries that have been proposed for my activity, I would like to 
comments separately the issues concerning protein PTM by transglutaminases and the 
basic and clinical oncology topics. In relation to the Protein Post-Translational 
Modification by Transglutaminases (in this case Tgase 2), it is clear that these are 
largely irreversible reactions. At this purpose I remind that reversibility has been proved 
only in the case of proteins linked to primary amines, notably Dansylcadaverine, because 
of the back-reaction of Tgase itself, as proved by Lorand and associates (Parameswaran et  
al, 1997). PTM by Tgases are likely to affect greatly the properties of modified proteins 
because of changes in surface charge (conversion of the glutamine amide groups into the  
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carboxylic acid of glutamate or into a primary amine through linkage with polyamine) or in 
solubility because of massive aggregation stabilized by isopeptide bonds. The  aggregated 
products are resistant to proteolysis because the isopeptide bond itself is not cleaved by 
proteases and because crosslinkage brings to an increased rigidity that is negative 
determinant of activity of proteases (Fontana). Historically the products of the 
transglutaminases reactions have been analyzed  by extensive cleavage by a cocktail of 
proteases to degrade PTM proteins containing glutamyl-lysine or glutamyl-polyamines 
isopeptide bonds to free aminoacids and small peptides that are resolved by HPLC 
chromatography to isolate the crosslinking isopeptide (Beninati et al, 1988), which is later 
determined by reaction with fluorescamine or o-Phtalaldehyde. By this procedure it is 
possible to prove and to quantify formation of isopeptide crosslinks in PTM proteins but 
not to identify the sites in the protein sequence at which the crosslink occurs. For this 
purpose the proteomic approach seems ideal with the limitation that it is difficult to 
determine directly the sequences involved in glutamyl-lysine isopeptides owing to the 
resistance to proteolysis. This information is best deduced from separate determination of 
labelling of reactive glutamine and lysine residues through incorporation of suitable 
probes. 
We followed this strategy in the published paper in the PTM of troponin T residues 
(Squerzanti et al, 2013) that is also reported in this Thesis, with the limitation that TnT is 
not a lysine substrate so that no protein crosslinkage occurs in this instance and 
determination of reactive lysine residues does not apply.  In this study we have employed 
the MALDI-TOF MS/MS approach and we considered that this might be the general 
procedure for this kind of determination. This conclusion however was dismantled as we 
tried to apply the same procedure to the identification of the sites of PTM of tubulin. At 
this purpose it is worthy to note a clear discrepancy in the data we have obtained, for which 
we have not yet any definitive explanation. The matter is related to the eventual 
polymerization of the tubulin protein, which appears to be minimal by the analysis of the 
residual band of monomeric tubulin by SDS-PAGE after reaction with Tgase 2 both in the 
absence and in the presence of an amino substrate, which should obviously inhibit any 
reaction of protein crosslinkage. The point I want to discuss is related to the gel of fig. 5.5 
which depicts the results of an experiment of PTM in the presence of dansylcadaverine. 
From the picture fluoresce is clearly present both in the separation and in the stacking gel. 
In the separation gel it is present with mild intensity in correspondence of the region of  
migration of the residual tubulin monomers while in the stacking gel it is present as a very  
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intense signal in the well, which however contains tiny amount of protein, which should be 
represented by aggregated insoluble protein which does not “enter” the gel. A priori this 
aggregated protein should arise from isopeptide crosslinked tubulin (i) aggregation should 
be very limited as already discussed and actually (ii) aggregation should also be inhibited 
by the presence of Dansylcadaverine which should compete with lysine for covalent 
binding to glutamine. At the same time it is important to realize that the very intense 
fluorescent signal produced by very tiny amount of protein actually displays a high 
“specific intensity” to employ an enzymologic concept, which is contrast with low 
labelling of monomeric tubulin subunits. In other words it is rather conceivable that an 
initial labelling of tubulin at a single or a few glutamine residues would affect protein 
solubility leading to large insolubility of the protein with conformational changes that 
allow a much more intense labelling by the fluorescence  probe. Beside this effect, what is 
more important to note in relation to the concept of suitability of proteomics to detect sites 
of protein PTM by Tgase 2 is the failure we had to identify glutamine and lysine residues 
separately labelled in tubulin by Dansylcadaverine and by Cbz-Glngly, employing 
MALDI-TOF MS/MS as the analytical strategy. The more likely explanation of this 
failure, as explained before, is concerned with the primary structure of tubulin itself and 
with clustering of acidic residues in the C-terminal region producing tryptic peptides of 
low ionization capability. Attempts to solve this point by alternative procedures are still 
underway by employing other proteases of different sequence specificity with in-gel-
digestion or alternatively to perform proteolysis in solution. By some authors (Sinz, 2006; 
Grebe and Singh, 2011) this last approach is considered superior to in-gel-digestion 
although it has drawbacks not to provide immediate imaging of the experimental results 
and to require a much more extensive access to mass spectrometry. On the bases of these 
results it is therefore important to underline the necessity of wide instrumental availability 
for extensive investigations of Tgase mediated protein PTM (Serpa et al, 2012).  
The last experimental system of protein PTM on which I focused is related to CRM197. 
This protein is now employed also as a carrier for vaccine development for encapsulated 
Gram-positive and negative bacteria including Haemophilus influenzae, Diplococcus 
pneumoniae and Neisseria meningiditis (Malito et al, 2012), along with its use in the 
therapy of haematologic malignancies. In the case of the mutant DT CRM197, the PTM by 
Tgase 2 is characterized by extensive crosslinkage, which suggests the possibility to 
employ DT as a carrier for intracellular release of peptides for either vaccination of 
therapeutic purposes, after specific crosslinkage to CRM197. It is the aim of the laboratory 
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to explore further these effects in the perspective of the possible biotechnologic application 
of CRM197 in the vaccine and therapeutic field.   
In contrast with these words of caution against the simple use of the MALDI-TOF MS/MS 
approach in the case of analysis of PTM by Tgase 2, this procedure proved reliable in our 
studies on cancer, for the analysis of the altered protein expression pattern both for the 
identification of candidate cancer cell markers and to investigate the basic feature of cancer 
cells. In this last aim we investigated the EMT process which determines their invasion 
characteristics of cancer cells, with relevance to the emergence of resistance to 
chemotherapy and radiation therapy as well as to the selective growth pressure of Cancer 
Stem Cells. An intriguing property of cancer growth is represented by the roles of 
proteases that are clearly involved in local spreading and in invasion of vessels. This role 
to control what could be called Cellular Adhesiveness involves chiefly extracellular 
proteases like the membrane Matrix Metallo Proteinases (MMP) (Knapinska and Fields, 
2012). In addition also intracellular proteases serve important signalling functions (Turk et 
al, 2012) also in cancer cells, in particular in the regulation of cell growth and death, 
mainly through the apoptotic program (Fiandalo and Kyprianou, 2012). 
I mentioned these effects to call attention on the cautions required to avoid artefacts when 
analysing protein composition in cancer specimens because the high content of proteases 
can eventually modify the pattern of expressed proteins, eventually degrading those that 
are more sensitive to proteolytic cleavage.  This is particularly relevant when denaturation 
prone buffers are employed, as it is the case with the TUC (Thiourea, Urea, Chaps) which 
is mandatory for a nice solubilisation of proteins particularly from pathologic tissues that 
might have been exposed to inflammatory conditions in vivo and therefore display 
extensive fibrosis. The effective solubilisation brought about by TUC buffer promotes 
indeed protein unfolding thus exposing to attack by proteases of internal protein regions 
that are normally protected from nicking because they are not available to the protease 
active site (Fontana, 1991; Hubbard, 1998). These precautions obviously do not apply so 
stringently in in vitro reconstructed models, as in the case of protein PTM, where presence 
of proteases is certainly better controlled.  
These difficulties can therefore be circumvented by means of addition of mixtures of 
inhibitors of  proteases, the so-called inhibitor cocktails, that include inhibitors to most 
type of proteases (serine, cysteine, acidic and metal proteases). Under these conditions 
reliable and reproducible extraction of tissue proteins has been achieved with a  
solubilisation buffer that is suitable for IEF although containing a zwitterionic detergent.  
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Coming more closely to the experimental results in the two systems pertinent to clinical 
oncology that we have explored up to now we have confirmed altered protein expression 
both in comparison between healthy and affected tissue from the same patient or in cancer 
cell lines cultured under conditions that facilitate the assumption of a more aggressive 
phenotype. In the case of infiltrating duct breast carcinoma many proteins displayed altered 
expression - in most cases increased expression-  when compared with normal  breast, with 
proteins mainly related to the function of the cytoskeletal motility and of protein folding 
and transmembrane transport (including heat shock proteins). Also the protein expression 
in cholangiocarcinoma cell lines is altered during culture. At the time I am writing it was 
yet possible to give information of the proteins that are more clearly affected, but I hope 
this information will be available the day of my presentation. 
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